Document_and_Entity_Informatio
Document and Entity Information Document | 9 Months Ended | |
Sep. 30, 2013 | Nov. 11, 2013 | |
Entity Information [Line Items] | ' | ' |
Entity Registrant Name | 'SPIRE Corp | ' |
Entity Central Index Key | '0000731657 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Document Type | '10-Q | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Amendment Flag | 'false | ' |
Entity Common Stock, Shares Outstanding | ' | 9,207,874 |
Consolidated_Balance_Sheets_St
Consolidated Balance Sheets Statement (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets | ' | ' |
Cash and Cash Equivalents | $5,897 | $3,030 |
Restricted cash | 170 | 0 |
Accounts receivable – trade, net | 1,363 | 2,137 |
Inventories, net | 4,656 | 5,316 |
Deferred cost of goods sold | 92 | 185 |
Deposits on equipment for inventory | 115 | 69 |
Prepaid expenses and other current assets | 821 | 617 |
Current assets of discontinued operations and assets held for sale | 0 | 718 |
Total current assets | 13,114 | 12,072 |
Property and equipment, net | 959 | 1,197 |
Intangible and other assets, net | 397 | 393 |
Available-for-sale investments, at quoted market value (cost of $2,250 and $2,204 at September 30, 2012 and December 31, 2011, respectively) | 3,225 | 2,963 |
Total assets | 17,695 | 16,625 |
Current liabilities | ' | ' |
Current portion of capital lease obligation | 11 | 13 |
Long-term Debt, Current Maturities | 745 | 0 |
Revolving line of credit | 581 | 590 |
Accounts payable | 1,712 | 1,424 |
Accrued liabilities | 3,280 | 2,221 |
Advances on contracts in progress | 1,046 | 1,037 |
Liabilities of discontinued operations | 21 | 171 |
Total current liabilities | 7,396 | 5,456 |
Long-term portion of capital lease obligation | 0 | 8 |
Long-term Debt, Excluding Current Maturities | 5,255 | 0 |
Deferred compensation | 3,225 | 2,963 |
Other long-term liabilities | 731 | 746 |
Total long-term liabilities | 9,211 | 3,717 |
Total liabilities | 16,607 | 9,173 |
Stockholders’ equity | ' | ' |
Common stock, $0.01 par value; 20,000,000 shares authorized; 8,562,633 shares issued and outstanding on September 30, 2012 and December 31, 2011, respectively | 93 | 91 |
Additional paid-in capital | 23,255 | 23,084 |
Accumulated deficit | -22,400 | -15,945 |
Accumulated other comprehensive income | 327 | 222 |
Total Spire Corporation stockholders’ equity | 1,275 | 7,452 |
Noncontrolling Interest in Variable Interest Entity | -187 | 0 |
Stockholders' Equity | 1,088 | 7,452 |
Total liabilities and stockholders’ equity | $17,695 | $16,625 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, except Share data, unless otherwise specified | ||
Available-for-sale investments, at quoted market value, cost | $2,898 | $2,741 |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 20,000,000 | 20,000,000 |
Common stock, shares issued | 9,207,874 | 9,062,633 |
Common stock, shares outstanding | 9,207,874 | 9,062,633 |
Consolidated_Statement_of_Oper
Consolidated Statement of Operation Statement (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Net sales and revenues | ' | ' | ' | ' |
Sales of goods | $1,776 | $1,858 | $4,213 | $11,796 |
Contract research and service revenues | 2,378 | 2,370 | 6,753 | 6,527 |
Total net sales and revenues | 4,154 | 4,228 | 10,966 | 18,323 |
Cost of sales and revenues | ' | ' | ' | ' |
Cost of goods sold | 1,868 | 2,048 | 5,561 | 10,470 |
Cost of contract research and services | 1,101 | 1,228 | 3,482 | 3,702 |
Total cost of sales and revenues | 2,969 | 3,276 | 9,043 | 14,172 |
Gross margin | 1,185 | 952 | 1,923 | 4,151 |
Operating expenses | ' | ' | ' | ' |
Selling, general and administrative expenses | 3,381 | 2,934 | 8,466 | 9,338 |
Internal research and development expenses | 15 | 36 | 38 | 227 |
Total operating expenses | 3,396 | 2,970 | 8,504 | 9,565 |
Operating loss from continuing operations | -2,211 | -2,018 | -6,581 | -5,414 |
Interest expense, net | -20 | -30 | -49 | -97 |
Foreign exchange gain (loss) | 0 | -9 | -9 | -6 |
Total other expense, net | -20 | -39 | -58 | -103 |
Loss from continuing operations before income tax benefit (provision) | -2,231 | -2,057 | -6,639 | -5,517 |
Income tax benefit (provision) - continuing operations | -1 | 24 | -3 | 2,016 |
Loss from continuing operations | -2,232 | -2,033 | -6,642 | -3,501 |
Loss from discontinued operations before sale of business unit | 0 | -250 | 0 | -680 |
Gain on sale of business unit, net of transaction expenses | 0 | 0 | 0 | 5,449 |
Income tax provision - discontinued operations | 0 | 0 | 0 | 2,008 |
Income from discontinued operations, net of tax | 0 | -250 | 0 | 2,761 |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | -2,232 | -2,283 | -6,642 | -740 |
Noncontrolling Interest in Variable Interest Entity | -187 | ' | -187 | ' |
Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest | -187 | 0 | -187 | 0 |
Net Income (Loss) Attributable to Noncontrolling Interest | ' | 0 | -187 | 0 |
Net income (loss) | ($2,045) | ($2,283) | ($6,455) | ($740) |
Basic income (loss) per share: | ' | ' | ' | ' |
From continuing operations, net of tax | ($0.22) | ($0.24) | ($0.70) | ($0.41) |
From discontinued operations, net of tax | $0 | ($0.03) | $0 | $0.32 |
Basic income (loss) per share | ($0.22) | ($0.27) | ($0.70) | ($0.09) |
Diluted income (loss) per share: | ' | ' | ' | ' |
From continuing operations, net of tax | ($0.20) | ($0.24) | ($0.70) | ($0.41) |
From discontinued operations, net of tax | $0 | ($0.03) | $0 | $0.32 |
Diluted income (loss) per share | ($0.20) | ($0.27) | ($0.70) | ($0.09) |
Weighted average number of common and common equivalent shares outstanding – basic | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 |
Weighted average number of common and common equivalent shares outstanding – diluted | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 |
Consolidated_Statement_of_Comp
Consolidated Statement of Comprehensive Income (Loss) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Comprehensive income (loss): | ' | ' | ' | ' |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($2,232) | ($2,283) | ($6,642) | ($740) |
Other comprehensive income (loss): | ' | ' | ' | ' |
Change in unrealized gain (loss) on available for sale marketable securiteis, net of tax | -2 | 107 | 105 | 216 |
Total comprehensive income (loss) | -2,047 | -2,176 | -6,350 | -524 |
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | -2,234 | -2,176 | -6,537 | -524 |
Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest | ($187) | $0 | ($187) | $0 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows Statement (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Cash flows from operating activities: | ' | ' |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($6,642) | ($740) |
Less: Net Income from discontinued operations, net of tax | 0 | 2,761 |
Loss from continuing operations | -6,642 | -3,501 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 364 | 641 |
Deferred tax benefit | 0 | -2,008 |
Deferred compensation | 105 | 216 |
Share-based Compensation | 88 | 169 |
Provision for accounts receivable reserve | 18 | 17 |
Provision for inventory reserve | 191 | 257 |
Changes in assets and liabilities: | ' | ' |
Restricted cash | -170 | 21 |
Accounts receivable | 756 | 1,613 |
Inventories | 469 | 1,137 |
Deferred cost of goods sold | 93 | 86 |
Deposits, prepaid expenses and other current assets | -250 | 573 |
Accounts payable, accrued liabilities and other liabilities | 1,417 | -2,873 |
Deposit - related party | 0 | 300 |
Advances on contracts in progress | 9 | -1,187 |
Net cash used in operating activities of continuing operations | -3,552 | -4,539 |
Net cash provided by operating activities of discontinued operations | -150 | -1,726 |
Net cash used in operating activities | -3,702 | -6,265 |
Cash flows from investing activities: | ' | ' |
Purchase of Property and Equipment | -86 | -129 |
Additions to intangible and other assets | -44 | -11 |
Net cash used in investing activities of continuing operations | -130 | -140 |
Net cash provided by investing activities of discontinued operations | 718 | 6,859 |
Net cash provided by investing activities | 588 | 6,719 |
Cash flows from financing activities: | ' | ' |
Principal payments on capital lease obligations | -10 | -34 |
Proceeds from Issuance of Long-term Debt | 6,000 | 0 |
Principal Payments on Revolving Line of Credit, Net | 9 | 0 |
Net cash used in financing activities | 5,981 | -34 |
Net increase (decrease) in cash and cash equivalents | 2,867 | 420 |
Cash and cash equivalents, beginning of period | 3,030 | 4,758 |
Cash and cash equivalents, end of period | 5,897 | 5,178 |
Supplemental disclosures of cash flow information: | ' | ' |
Interest paid | 49 | 97 |
Income Taxes Paid | 1 | 10 |
Supplemental disclosure of non-cash flow information [Abstract] | ' | ' |
Liabilities settled with common stock | 84 | 0 |
Inventory transfered to property and equipment | 0 | 405 |
Dividends | $9,540 | $0 |
Description_of_Business
Description of Business | 9 Months Ended |
Sep. 30, 2012 | |
Description of the Business [Abstract] | ' |
Description of the Business [Text Block] | ' |
Description of the Business | |
Spire Corporation ("Spire" or the "Company") and its subsidiaries along with its variable interest entity develop, manufacture and market highly-engineered products and services in two principal business areas: (i) capital equipment and systems for the photovoltaic solar industry and (ii) biomedical, through its variable interest entity, N2 Biomedical LLC ("N2 Bio"), generally bringing to bear expertise in materials technologies, surface science and thin films across both business areas, discussed below. | |
In the photovoltaic solar area, the Company develops, manufactures and markets specialized equipment for the production of terrestrial photovoltaic modules from solar cells and provide photovoltaic systems for grid connected applications in the commercial markets. The Company's equipment has been installed in approximately 200 factories in 50 countries. The equipment market is very competitive with major competitors located in the U.S., Japan and Europe. The Company's flagship product is its Sun Simulator which tests module performance. The Company's other product offerings include turn-key module lines and to a lesser extent other individual equipment. To compete the Company offers other services such as training and assistance with module certification. The Company also provides turn-key services to its customers to backward integrate to solar cell manufacturing. | |
In the biomedical area, through its variable interest entity, N2 Bio, the Company provides value-added surface treatments to manufacturers of orthopedic and other medical devices that enhance the durability, antimicrobial characteristics or other material characteristics of their products; and performs sponsored research programs into practical applications of advanced biomedical technologies. | |
Transactions | |
On September 18, 2013, the Company, Spire Biomedical, Inc. (the “Subsidiary” and together with the Company, “Spire Bio”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with N2 Bio pursuant to which N2 Bio agreed to (i) acquire substantially all of the assets of the Subsidiary's biomedical business (the “Bio Business Unit”) and (ii) assume and pay certain liabilities related to the purchased assets as set forth in the Purchase Agreement (collectively, the “Transaction”). The Transaction closed on September 18, 2013. The purchase price for the Bio Business Unit was $10.5 million plus the assumption of liabilities of approximately $100 thousand, with $6.0 million paid in cash at closing, a $2.4 million subordinated convertible promissory note, and 310,549 Series A Convertible Preferred Units of N2 Bio valued at approximately $2.1 million ($6.72 per share). The assets and liabilities of the Subsidiary's biomedical business are under common control and requires carryover basis for financial reporting. The difference between the consideration paid and the carrying value of the assets and liabilities acquired by N2 Bio was recorded as a deemed dividend to the Company in the amount of $9.5 million and has been eliminated in consolidation. Mark C. Little was the Chief Executive Officer of the Subsidiary, is a director of the Company and is the Chief Executive Officer of N2 Bio. Mark C. Little is the son of Roger G. Little, Chief Executive Officer of the Company. | |
The Company has determined that N2 Bio is a variable interest entity ("VIE") because the equity investment at risk from the majority shareholders of N2 Bio is not sufficient to permit N2 Bio to finance its activities without additional subordinated financial support from the Company. As discussed above, N2 Bio is subject to a subordinated convertible promissory note. Additionally, Mark Little is the Chief Executive Officer of N2 Bio and also a director of the Company which qualifies as a related party. The Company has also determined that the Company has the obligation to absorb losses and the right to receive benefits from N2 Bio that could potentially be significant to it. Therefore, the Company has determined that N2 Bio is a VIE and must consolidate the financial condition, results of operations and cash flows of N2 Bio with those of its own. See Note 14 to the unaudited condensed consolidated financial statements. | |
The subordinated convertible promissory note (i) bears interest at 9% per annum until paid in full, (ii) is convertible, at Company's option, into Common Units of N2 Bio at a conversion price of $6.72 per share, (iii) has a seven year term, (iv) is unsecured and (v) is subordinate in right of payment to all senior bank indebtedness of N2 Bio. | |
The Series A Convertible Preferred Units (i) represent an equity ownership interest of 19.9% in N2 Bio, (ii) are governed by the terms of the Amended and Restated Limited Liability Company Agreement of N2 Bio dated September 18, 2013, (iii) rank senior to the Common Units on liquidation, dissolution and winding up, and (iv) vote together with the Common Units on an as-converted basis. The Company has the right to appoint one director to the Board of Directors of N2 Bio. N2 Bio is subject to certain affirmative and negative operating covenants in favor of the holder of Series A Preferred Units. | |
On September 18, 2013, the Company and N2 Bio entered into a Shared Services Agreement whereby the Company will provide N2 Bio certain services (the “Shared Services”) for a period of three years. It is the intent of the parties that the aggregate fees for the Shared Services shall equal approximately $500 thousand during the first year. Following the first anniversary, N2 Bio may terminate any specific Shared Service with 20 days' written notice to the Company. | |
On September 18, 2013, the lease agreement between SPI-Trust and the Company for the premises in Bedford, Massachusetts where the Business is located was amended, by reducing the Company's leased space and annual base rent by approximately 19%. All other material terms and conditions related to the lease remain unchanged as of such date. | |
On September 18, 2013, N2 Bio entered into a Lease Agreement (the “N2 Bio Bedford Lease”) with SPI-Trust with respect to 27 thousand square feet of space in the premises in Bedford, Massachusetts. The term of the N2 Bio Bedford Lease commenced on September 18, 2013 and is set to expire on November 30, 2020. The annual rental rate prorated for September 18, 2013 to November 30, 2013 is $16.00 per square foot on a triple net basis, whereby the tenant is responsible for operating expenses, taxes and maintenance of the building. The annual rental rate increases on December 1, 2013 and each anniversary thereafter by $0.50 per square foot. | |
The Purchase Agreement includes a five-year commitment of (i) the Company not to compete with the Bio Business Unit services and (ii) N2 Bio not to compete with the consumer electronic products business of the Company. Both the Company and N2 Bio agreed not to solicit the officers or employees of the other party for a one-year period. | |
On March 9, 2012, the Company completed the sale of its semiconductor business unit, which provided semiconductor foundry services, operated a semiconductor foundry and fabrication facility and was engaged in the business of wafer epitaxy, foundry services, and device fabrication for the defense, medical, telecommunications and consumer products markets (the “Semiconductor Business Unit”), to Masimo Corporation ("Masimo"). Accordingly, the results of operations and assets and liabilities of the Semiconductor Business Unit are being presented herein as discontinued operations. See Note 13 to the unaudited condensed consolidated financial statements. | |
Liquidity | |
Operating results will depend upon revenue growth or decline and product mix, as well as the timing of shipments of higher priced products from the Company's solar equipment line and delivery of solar systems. Export sales, which amounted to 27% and 31% of net sales and revenues for the three and nine months ended September 30, 2013, respectively, and 29% and 57% of net sales and revenues for both the three and nine months ended September 30, 2012, respectively, continue to constitute a significant portion of the Company's net sales and revenues. | |
The Company has incurred operating losses from continuing operations. Operating loss from continuing operations was $2.2 million and $6.6 million for the three and nine months ended September 30, 2013, respectively. Operating loss from continuing operations was $2.0 million and $5.4 million for the three and nine months ended September 30, 2012, respectively. Net cash used in operating activities was $3.7 million for the nine months ended September 30, 2013, which includes $150 thousand of cash used in operating activities of discontinued operations. Net cash used in operating activities was $6.3 million for the nine months ended September 30, 2012, which includes $1.7 million of cash used in operating activities of discontinued operations. As of September 30, 2013, the Company had unrestricted cash and cash equivalents of $5.9 million compared to $3.0 million as of December 31, 2012. The maturity date of the Company's credit facilities with Silicon Valley Bank is April 30, 2014. The maturity date of N2 Bio's revolving credit facility with Middlesex Savings Bank is September 18, 2014. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company currently believes that its existing cash resources at September 30, 2013, will be sufficient to fund its operations into the first half of 2014; however, the Company cannot assure you of this. | |
The Company has various options on how to fund future operational losses and working capital needs, including but not limited to sales of equity, bank debt, the sale or license of assets and technology, or joint ventures involving cash infusions, as it has done in the past; however, there are no assurances that the Company will be able to sell equity, obtain or access bank debt, sell or license assets or technology or enter into such joint ventures on a timely basis and at appropriate values. The Company has developed several plans including potential strategic alternatives, cost reduction efforts and expanding revenue in other solar markets to offset a decline in business due to global economic conditions. The Company's inability to successfully implement its cost reduction strategies, expand revenue in other solar markets or to renew its credit facilities, could adversely impact the Company's ability to continue as a going concern. | |
Based on the forecasts and estimates underlying the Company's current operating plan, the financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
Interim_Financial_Statements
Interim Financial Statements | 9 Months Ended |
Sep. 30, 2013 | |
Interim Financial Statements [Abstract] | ' |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' |
Interim Financial Statements | |
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K filed with the SEC. | |
In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to fairly present the Company’s financial position as of September 30, 2013 and December 31, 2012 and the results of their operations for the three and nine months ended September 30, 2013 and 2012. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2013. The unaudited condensed consolidated balance sheet as of December 31, 2012 has been derived from audited financial statements as of that date. During the second quarter of 2009, the Company began pursing an exclusive sales process of its Medical Products Business Unit. On December 14, 2009, the Company completed the sale of the Medical Products Business Unit to Bard. During the first quarter of 2012, the Company began pursing an exclusive sales process of its Semiconductor Business Unit and on March 9, 2012, the Company completed the sale of the Semiconductor Business Unit to Masimo. Accordingly, the results of operations and assets and liabilities of the Semiconductor Business Unit and the liabilities of the Medical Products Business Unit are being presented herein as discontinued operations. See Note 13 to the unaudited condensed consolidated financial statements. | |
On September 18, 2013, the Company completed the sale of the Bio Business Unit to N2 Bio, whereas, the Company has a controlling financial interest in N2 Bio and is less than wholly-owned by the Company. Accordingly, the unaudited condensed consolidated financial statements of the Company include the accounts of N2 Bio. The N2 Bio holding of equity interest is referred to as a noncontrolling interest. The portion of the net loss attributable to the noncontrolling interest of N2 Bio is presented as net loss attributable to noncontrolling interest in the unaudited condensed consolidated statements of operations and the portion of comprehensive loss attributable to the noncontrolling interest of N2 Bio is presented as comprehensive loss attributable to noncontrolling interests in the unaudited condensed consolidated statements of comprehensive loss. The portion of stockholders' equity of N2 Bio attributable to the noncontrolling interest of N2 Bio is presented as noncontrolling interest in the unaudited condensed consolidated balance sheets. | |
Summary of Significant Accounting Policies | |
With the exception of the Company's principals of consolidation which has been updated below, the significant accounting policies followed by the Company are set forth in Note 2 to the Company’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC. | |
Principles of Consolidation | |
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries along with its variable interest entity. All significant intercompany balances and transactions have been eliminated in consolidation. The portion of the net loss attributable to the noncontrolling interest of N2 Bio is presented as net loss attributable to noncontrolling interest in the unaudited condensed consolidated statements of operations and the portion of comprehensive loss attributable to the noncontrolling interest of N2 Bio is presented as comprehensive loss attributable to noncontrolling interests in the unaudited condensed consolidated statements of comprehensive loss. The portion of stockholders' equity of N2 Bio attributable to the noncontrolling interest of N2 Bio is presented as noncontrolling interest in the unaudited condensed consolidated balance sheets. | |
New Accounting Pronouncements | |
In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2013-11 ("ASU 2013-11"), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The update requires, unless certain conditions exists, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. ASU 2013-11 is effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted. Retrospective application is permitted. The Company is currently evaluating the impact of ASU 2013-11 yet there are no uncertain tax positions included in the unaudited condensed consolidated financial statements. | |
In December 2011, the FASB issued ASU No. 2011-11 ("ASU 2011-11"), Disclosures about Offsetting Assets and Liabilities. The update requires companies to disclose information about financial instruments that have been offset and related arrangements to enable users of their financial statements to understand the effect of those arrangements on their financial position. Companies will be required to provide both net (offset amounts) and gross information in the notes to the financial statements for relevant assets and liabilities that are offset. In January 2013, the FASB issued ASU No. 2013-01 (ASU 2013-01"), Clarifying the Scope of Disclosures About Offsetting Assets and Liabilities. The update limits the scope of the offsetting disclosures required by ASU 2011-11. ASU 2011-11 and ASU 2013-01 is effective for interim and annual periods beginning after December 31, 2012. As the requirements of these ASUs relate only to disclosures, the application of the updates did not have a material impact on the Company's unaudited condensed consolidated financial statements. | |
In December 2011, the FASB issued ASU No. 2011-12 ("ASU 2011-12"), Comprehensive Income: Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. ASU 2011-12 deferred the effective date of the specific requirement to present items that are reclassified out of accumulated other comprehensive income to net income alongside their respective components of net income and other comprehensive income. As part of this update, the FASB did not defer the requirement to report comprehensive income in either a single continuous statement or in two separate but consecutive statements. In February 2013, the FASB issued ASU No. 2013-02 ("ASU 2013-02"), Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 is effective for interim and annual periods beginning after December 31, 2012. As ASU 2013-02 relates to disclosure requirements only, the application of this update did not have a material impact on the Company's unaudited condensed consolidated financial statements. |
Accounts_ReceivableAdvances_on
Accounts Receivable/Advances on Contracts in Progress | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Accounts Receivable and Advances on Contracts in Progress [Abstract] | ' | |||||||
Accounts Receivables and Advances on Contracts in Progress [Text Block] | ' | |||||||
Accounts Receivable/Advances on Contracts in Progress | ||||||||
Net accounts receivable, trade and advances on contracts in progress consists of the following: | ||||||||
(in thousands) | September 30, 2013 | December 31, 2012 | ||||||
Amounts billed | $ | 1,365 | $ | 1,927 | ||||
Accrued revenue | 18 | 238 | ||||||
Gross accounts receivable - trade | 1,383 | 2,165 | ||||||
Less: Allowance for doubtful accounts | (20 | ) | (28 | ) | ||||
Net accounts receivable - trade | $ | 1,363 | $ | 2,137 | ||||
Advances on contracts in progress | $ | 1,046 | $ | 1,037 | ||||
Accrued revenue represents revenues recognized on contracts for which billings have not been presented to customers as of the balance sheet date. These amounts are billed and generally collected within one year. | ||||||||
The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay amounts due. The Company actively pursues collection of past due receivables as the circumstances warrant. Customers are contacted to determine the status of payment and senior accounting and operations management are included in these efforts as is deemed necessary. A specific reserve will be established for past due accounts when it is probable that a loss has been incurred and the Company can reasonably estimate the amount of the loss. The Company does not record an allowance for government receivables and invoices backed by letters of credit as collection is reasonably assured. Bad debts are written off against the allowance when identified. There is no dollar threshold for account balance write-offs. While rare, a write-off is only recorded when all efforts to collect the receivable have been exhausted. The Company received payments of $24 thousand and $10 thousand for the nine months ended September 30, 2013 and 2012, respectively, against amounts which had been previously reserved for in allowance for doubtful accounts. | ||||||||
Advances on contracts in progress represent billings that have been presented to the customer, as either deposits or progress payments against future shipments, but revenue has not been recognized. |
Inventories_and_Deferred_Costs
Inventories and Deferred Costs of Goods Sold | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventories and Deferred Costs of Goods Sold [Abstract] | ' | |||||||
Inventory and Deferred Costs of Goods Sold [Text Block] | ' | |||||||
Inventories and Deferred Costs of Goods Sold | ||||||||
Inventories, net of $1.1 million and $860 thousand of reserves at September 30, 2013 and December 31, 2012, respectively, and deferred cost of goods sold consist of the following at: | ||||||||
(in thousands) | September 30, | December 31, | ||||||
2013 | 2012 | |||||||
Raw materials | $ | 1,489 | $ | 1,784 | ||||
Work in process | 1,923 | 2,103 | ||||||
Finished goods | 1,244 | 1,429 | ||||||
Net inventory | $ | 4,656 | $ | 5,316 | ||||
Deferred cost of goods sold | $ | 92 | $ | 185 | ||||
The Company wrote-off $29 thousand of excess and obsolete inventory for the nine months ended September 30, 2012 and had no write-offs for the nine months ended September 30, 2013. | ||||||||
Deferred cost of goods sold represents costs of equipment that has shipped to the customer and title has passed but not all revenue recognition criteria have yet been met. The Company defers these costs until the related revenue is recognized. |
Income_loss_Per_Share
Income (loss) Per Share | 9 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Income (loss) Per Share [Abstract] | ' | |||||||||||
Earnings Per Share [Text Block] | ' | |||||||||||
Income (Loss) Per Share | ||||||||||||
The following table provides a reconciliation of the denominators of the Company’s reported basic and diluted income (loss) per share computations for the periods ended: | ||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||
Weighted average number of common and common equivalent shares outstanding – basic | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 | ||||||||
Add: Net additional common shares upon assumed exercise of common stock options | — | — | — | — | ||||||||
Adjusted weighted average number of common and common equivalents shares outstanding – diluted | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 | ||||||||
For the three and nine months ended September 30, 2013, 1,152 and 3,708 shares of common stock, respectively, and for the three and nine months ended September 30, 2012, 220 and 1,335 shares of common stock, respectively, issuable relative to stock options were excluded from the calculation of diluted shares because their inclusion would have been anti-dilutive, due to the Company’s net loss position. | ||||||||||||
In addition, for the three and nine months ended September 30, 2013, 559,571 and 535,571 shares of common stock, respectively, and for the three and nine months ended September 30, 2012, 629,446 and 619,446 shares of common stock, respectively, issuable relative to stock options were excluded from the calculation of diluted shares because their inclusion would have been anti-dilutive, due to the Company's net loss position and their exercise prices exceeding the average market price of the stock for the period. |
Operating_Segments_and_Related
Operating Segments and Related Information | 9 Months Ended | |||||||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||||||
Operating Segments and Related Information [Abstract] | ' | |||||||||||||||||||||||||||
Segment Reporting Disclosure [Text Block] | ' | |||||||||||||||||||||||||||
Operating Segments and Related Information | ||||||||||||||||||||||||||||
The Company's operations are focused on two primary business areas: Spire Solar (comprised of solar equipment, solar systems and solar research) and Spire Biomedical (comprised of biomedical surface treatments and biophotonics research). Spire Solar and Spire Biomedical operate out of the Company's facility in Bedford, Massachusetts. Each business area is independently managed and has separate financial results that are reviewed by the Board of Directors and Chief Executive Officer and the chief executive officers of each operating division. | ||||||||||||||||||||||||||||
On September 18, 2013, the Company completed the sale of the Bio Business Unit to N2 Bio, whereas, the Company has a controlling financial interest in N2 Bio and is less than wholly-owned by the Company. N2 Bio qualifies as a variable interest entity and the Company is determined to be the primary beneficiary, therefore assets, liabilities and results of operations of N2 Bio are consolidated into the Company's financial statements. The Bio Business Unit is being reported in our biomedical segment. See Note 14 to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||||||||
During the first quarter of 2012, the Company began pursuing an exclusive sales process of our semiconductor business and on March 9, 2012, the Company completed the sale of the Semiconductor Business Unit to Masimo Corporation. The Company reported the Semiconductor Business Unit as discontinued operations beginning with our financial results presented in our Quarterly Report on Form 10-Q for the first quarter of fiscal 2012. The Semiconductor Business Unit was previously reported as our optoelectronics segment. Accordingly, the results of operations and assets and liabilities of the Semiconductor Business Unit are being presented herein as discontinued operations and are not included in the table below. See Note 13 to the unaudited condensed consolidated financial statements. | ||||||||||||||||||||||||||||
The following table presents certain continuing operating division information in accordance with the provisions of ASC 280, Segments Reporting. | ||||||||||||||||||||||||||||
(in thousands) | Solar | Biomedical | Consolidated | |||||||||||||||||||||||||
For the three months ended September 30, 2013 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 2,445 | $ | 1,709 | 4,154 | |||||||||||||||||||||||
Operating loss from continuing operations | $ | (1,462 | ) | $ | (749 | ) | (2,211 | ) | ||||||||||||||||||||
For the three months ended September 30, 2012 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 2,485 | $ | 1,743 | 4,228 | |||||||||||||||||||||||
Operating income (loss) from continuing operations | $ | (2,197 | ) | $ | 179 | (2,018 | ) | |||||||||||||||||||||
For the nine months ended September 30, 2013 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 5,783 | $ | 5,183 | $ | 10,966 | ||||||||||||||||||||||
Operating loss from continuing operations | $ | (6,192 | ) | $ | (389 | ) | $ | (6,581 | ) | |||||||||||||||||||
For the nine months ended September 30, 2012 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 13,219 | $ | 5,104 | $ | 18,323 | ||||||||||||||||||||||
Operating income (loss) from continuing operations | $ | (5,740 | ) | $ | 326 | $ | (5,414 | ) | ||||||||||||||||||||
Operating loss from continuing operations is net sales less cost of sales and selling, general and administrative expenses, but is not affected by non-operating income (expense), by income taxes or by net income (loss) from discontinued operations. In calculating operating loss from continuing operations for individual business units, substantial administrative expenses incurred at the operating level that are common to more than one segment are allocated on a net sales basis. Certain corporate expenses of an operational nature are also allocated to the divisions based on factors including occupancy, employment, and purchasing volume. All intercompany transactions have been eliminated. Included in the Biomedical segment are costs associated with the sale of the biomedical assets to N2 Bio. | ||||||||||||||||||||||||||||
The following table shows net sales and revenues by geographic area (based on customer location): | ||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||
(in thousands) | 2013 | % | 2012 | % | 2013 | % | 2012 | % | ||||||||||||||||||||
United States | $ | 3,042 | 73 | % | $ | 3,005 | 71 | % | $ | 7,576 | 69 | % | $ | 7,955 | 43 | % | ||||||||||||
Europe/Africa | 874 | 21 | 376 | 9 | 1,664 | 15 | 3,062 | 17 | ||||||||||||||||||||
Asia | 238 | 6 | 839 | 20 | 1,509 | 14 | 7,246 | 40 | ||||||||||||||||||||
Rest of the world | — | — | 8 | — | 217 | 2 | 60 | — | ||||||||||||||||||||
$ | 4,154 | 100 | % | $ | 4,228 | 100 | % | $ | 10,966 | 100 | % | $ | 18,323 | 100 | % | |||||||||||||
Revenues from contracts with United States government agencies for the three months ended September 30, 2013 and 2012 were approximately $61 thousand and $392 thousand or 1% and 9% of total net sales and revenues, respectively. | ||||||||||||||||||||||||||||
Revenues from contracts with United States government agencies for the nine months ended September 30, 2013 and 2012 were approximately $704 thousand and $1.3 million or 6% and 7% of total net sales and revenues, respectively. | ||||||||||||||||||||||||||||
Revenues from the delivery of biomedical services to one customer accounted for 17% of total net sales and revenues for the three month period ended September 30, 2013. Revenues from the delivery of solar equipment to one customer accounted for 13% of total net sales and revenues for the three month period ended September 30, 2013. Revenues from the delivery of solar equipment research and development to one customer accounted for 14% of total net sales and revenues for the three month period ended September 30, 2013. Revenues from the delivery of solar systems to one customer accounted for 15% of total net sales and revenues for the three month period ended September 30, 2013. | ||||||||||||||||||||||||||||
Revenues from the delivery of biomedical services to two customers accounted for 20% and 11% of total net sales and revenues for the nine month period ended September 30, 2013. | ||||||||||||||||||||||||||||
Revenues from the delivery of biomedical services to one customer accounted for 19% of total net sales and revenues for the three month period ended September 30, 2012. | ||||||||||||||||||||||||||||
Revenues from the delivery of solar equipment to two customers account for 12% and 10% of total net sales and revenues for the nine month period ended September 30, 2012. Revenues from the delivery of biomedical services to one customer accounted for 12% of total net sales and revenues for the nine month period ended September 30, 2012. | ||||||||||||||||||||||||||||
Three customers represented approximately 25%, 17% and 20%, respectively, of net accounts receivable, trade at September 30, 2013 and one customer represented approximately 24% of net accounts receivable, trade at December 31, 2012. |
Intangible_and_Other_Assets
Intangible and Other Assets | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Intangible and Other Assets [Abstract] | ' | ||||
Intangible and Other Assets [Text Block] | ' | ||||
Intangible and Other Assets | |||||
Patents amounted to $74 thousand and $111 thousand, net of accumulated amortization of $859 thousand and $822 thousand, at September 30, 2013 and December 31, 2012, respectively. Licenses amounted to $56 thousand and $60 thousand, net of accumulated amortization of $19 thousand and $15 thousand, at September 30, 2013 and December 31, 2012, respectively. Patent cost is primarily composed of costs associated with securing and registering patents that the Company has been awarded or that have been submitted to, and the Company believes will be approved by the government. License cost is composed of the cost to acquire rights to the underlying technology or know-how. These costs are capitalized and amortized over their useful lives or terms, ordinarily five years using the straight-line method. There are no expected residual values related to these patents. Amortization expense from continuing operations, relating to patents and licenses, was approximately $14 thousand and $44 thousand for the three months ended September 30, 2013 and 2012, respectively. Amortization expense from continuing operations, relating to patents and licenses, was approximately $41 thousand and $84 thousand for the nine months ended September 30, 2013 and 2012, respectively. | |||||
For disclosure purposes, the table below includes future amortization expense for patents and licenses owned by the Company as well as estimated amortization expense related to patents that remain pending at September 30, 2013 of $117 thousand. This estimated expense for patents pending assumes that the patents are issued immediately, and therefore are being amortized over five years on a straight-line basis. Estimated amortization expense for the periods ending December 31, is as follows: | |||||
(in thousands) | Amortization Expense | ||||
2013 remaining 3 months | $ | 21 | |||
2014 | 69 | ||||
2015 | 50 | ||||
2016 | 28 | ||||
2017 | 28 | ||||
2018 | 23 | ||||
Thereafter | 28 | ||||
$ | 247 | ||||
Also included in other assets are refundable deposits made by the Company of approximately $150 thousand and $154 thousand at September 30, 2013 and December 31, 2012, respectively. |
AvailableforSale_Investments
Available-for-Sale Investments | 9 Months Ended |
Sep. 30, 2013 | |
Available-for-Sale Investments [Abstract] | ' |
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | ' |
Available-for-Sale Investments | |
Available-for-sale investments consist of assets held as part of the Spire Corporation Non-Qualified Deferred Compensation Plan. These investments have been classified as available-for-sale investments and are reported at fair value, with unrealized gains and losses included in accumulated other comprehensive income. The unrealized gain on these marketable securities was $327 thousand and $222 thousand as of September 30, 2013 and December 31, 2012, respectively. Additionally, the Company settled $84 thousand of accrued liabilities through issuance of common stock to the Spire Corporation Non-Qualified Deferred Compensation Plan during the nine month period ended September 30, 2013. |
Fair_Value_Measurements
Fair Value Measurements | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Fair Value Measurements [Abstract] | ' | |||||||||||||||
Fair Value Disclosures [Text Block] | ' | |||||||||||||||
Fair Value Measurements | ||||||||||||||||
The hierarchy established under ASC 820-10, Fair Value Measures and Disclosures ("ASC 820-10") gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). As required by ASC 820-10, the Company's available-for-sale investments are classified within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The three levels of the fair value hierarchy under ASC 820-10, and its applicability to the Company's available-for-sale investments, are described below: | ||||||||||||||||
Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, the Company does not adjust the quoted price for these investments, even in situations where the Company holds a large position and a sale could reasonably impact the quoted price. | ||||||||||||||||
Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. | ||||||||||||||||
Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. | ||||||||||||||||
Valuation Techniques | ||||||||||||||||
Fair value is a market-based measure considered from the perspective of a market participant who would buy the asset or assume the liability rather than the Company's own specific measure. All of the Company's fixed income securities are priced using a variety of daily data sources, largely readily-available market data and broker quotes. To validate these prices, the Company compares the fair market values of the Company's fixed income investments using market data from observable and corroborated sources. The Company also performs the fair value calculations for its common stock and mutual fund securities using market data from observable and corroborated sources. In periods of market inactivity, the observability of prices and inputs may be reduced for certain instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2 or from Level 2 to Level 3. During the nine months ended September 30, 2013, none of the Company's instruments were reclassified between Level 1, Level 2, Level 3 and there have been no changes in valuation techniques. | ||||||||||||||||
The following table presents the financial instruments related to the Company’s available-for-sale investment carried at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 by ASC 820-10 valuation hierarchy (as defined above). | ||||||||||||||||
(in thousands) | Balance as of | Level 1 | Level 2 | Level 3 | ||||||||||||
30-Sep-13 | ||||||||||||||||
Cash and short term investments | $ | 87 | $ | 87 | $ | — | $ | — | ||||||||
Common stock | ||||||||||||||||
Basic Materials | 22 | 22 | — | — | ||||||||||||
Consumer Goods | 143 | 143 | — | — | ||||||||||||
Energy | 120 | 120 | — | — | ||||||||||||
Financial | 149 | 149 | — | — | ||||||||||||
Healthcare | 138 | 138 | — | — | ||||||||||||
Industrial Goods | 158 | 158 | — | — | ||||||||||||
Services | 34 | 34 | — | — | ||||||||||||
Technology | 464 | 464 | — | — | ||||||||||||
Transportation | — | — | — | — | ||||||||||||
Utilities | 14 | 14 | — | — | ||||||||||||
Total Common Stock | 1,242 | 1,242 | — | — | ||||||||||||
Mutual Fund | ||||||||||||||||
Diversified Emerging Markets | 289 | — | 289 | — | ||||||||||||
Foreign Large Blend | 265 | — | 265 | — | ||||||||||||
Foreign Large Growth | 273 | — | 273 | — | ||||||||||||
Large Growth | 250 | — | 250 | — | ||||||||||||
Small Blend | 293 | 293 | — | — | ||||||||||||
Global High Yield Income Fund | 56 | — | 56 | — | ||||||||||||
Total Mutual Fund | 1,426 | 293 | 1,133 | — | ||||||||||||
Fixed Income | ||||||||||||||||
Domestic | 421 | — | 421 | — | ||||||||||||
International | 49 | — | 49 | — | ||||||||||||
Total Fixed Income | 470 | — | 470 | — | ||||||||||||
Total available-for-sale investments (1) | $ | 3,225 | $ | 1,622 | $ | 1,603 | $ | — | ||||||||
Percent of total | 100 | % | 50 | % | 50 | % | — | % | ||||||||
(in thousands) | Balance as of December 31, 2012 | Level 1 | Level 2 | Level 3 | ||||||||||||
Cash and short term investments | $ | 32 | $ | 32 | $ | — | $ | — | ||||||||
Common Stock | ||||||||||||||||
Basic Materials | 15 | 15 | — | — | ||||||||||||
Consumer Goods | 58 | 58 | — | — | ||||||||||||
Energy | 29 | 29 | — | — | ||||||||||||
Financial | 61 | 61 | — | — | ||||||||||||
Healthcare | 52 | 52 | — | — | ||||||||||||
Industrial Goods | 51 | 51 | — | — | ||||||||||||
Services | 32 | 32 | — | — | ||||||||||||
Technology | 376 | 376 | — | — | ||||||||||||
Transportation | 8 | 8 | — | — | ||||||||||||
Utilities | 26 | 26 | — | — | ||||||||||||
Total Common Stock | 708 | 708 | — | — | ||||||||||||
Mutual Fund | ||||||||||||||||
Diversified Emerging Markets | 187 | — | 187 | — | ||||||||||||
Precious Metals Fund | 49 | — | 49 | — | ||||||||||||
Foreign Large Blend | 244 | — | 244 | — | ||||||||||||
Foreign Large Growth | 250 | — | 250 | — | ||||||||||||
Large Growth | 220 | — | 220 | — | ||||||||||||
Small Blend Total | 525 | 525 | — | — | ||||||||||||
Global High Yield Income Fund | 52 | — | 52 | — | ||||||||||||
Total Mutual Funds | 1,527 | 525 | 1,002 | — | ||||||||||||
Fixed Income | ||||||||||||||||
Domestic | 678 | — | 678 | — | ||||||||||||
International | 18 | — | 18 | — | ||||||||||||
Total Fixed Income | 696 | — | 696 | — | ||||||||||||
Total available for-sale-investments (1) | $ | 2,963 | $ | 1,265 | $ | 1,698 | $ | — | ||||||||
Percent of total | 100 | % | 43 | % | 57 | % | — | % | ||||||||
(1) | Changes in the fair value of available-for-sale investments are recorded in accumulated other comprehensive income, a component of stockholders’ equity, in the Company’s unaudited condensed consolidated balance sheets. | |||||||||||||||
The carrying amounts reflected in the Company's unaudited condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, and capital lease obligations approximate fair value due to their short-term maturities. The fair value of the Company's term loan and revolving lines of credit have been estimated by management based on the terms that it believes it could obtain in the current market for debt of the same terms and similar remaining maturities. Due to the short-term nature of the remaining maturities, recent issuances, frequency of amendments to its terms and the variable interest rates, the carrying value of the term loan and revolving lines of credit approximate fair value at September 30, 2013 and December 31, 2012. |
Notes_Payable_and_Credit_Arran
Notes Payable and Credit Arrangements | 9 Months Ended |
Sep. 30, 2013 | |
Notes Payable and Credit Arrangements [Abstract] | ' |
Debt Disclosure [Text Block] | ' |
Notes Payable and Credit Arrangements | |
The Company has two separate credit facilities with Silicon Valley Bank (the “Bank” or “SVB”): (i) a Second Amended and Restated Loan and Security Agreement (as amended, the "Revolving Credit Facility") and (ii) an Amended and Restated Export-Import Bank Loan and Security Agreement (as amended, the "Ex-Im Facility") pursuant to which outstanding amounts under this facility are guaranteed by the Export-Import Bank of the United States (the “EXIM Bank”). The credit facilities provide an aggregate amount of $1.5 million under both facilities, with up to $1.0 million available under the Revolving Credit Facility and up to $1.5 million available under the Ex-Im Facility. In addition, a guidance line supports letters of credit in an aggregate amount of up to $1.5 million through April 30, 2014. If the Company achieves certain levels of liquidity, based on cash on hand and availability under the credit facility, the Company will not be required to cash collateralize letters of credit issued under this guidance line. | |
On September 3, 2013, the Company and the Bank entered into (i) the Sixth Loan Modification Agreement amending certain terms of the Second Amended and Restated Loan and Security Agreement dated as of November 16, 2009 (as amended, the “Revolving Credit Facility”) and (ii) the Sixth Loan Modification Agreement amending certain terms of the Amended and Restated Export-Import Bank Loan and Security Agreement dated as of November 16, 2009 (as amended, the “Ex-Im Facility”). Pursuant to the terms of the Sixth Loan Modification Agreements, the Company and the Bank agreed to extend the maturity date of the Revolving Credit Facility and the Ex-Im Facility to October 29, 2013. | |
On November 18, 2013, the Company and the Bank entered into (i) the Seventh Loan Modification Agreement amending certain terms of the Second Amended and Restated Loan and Security Agreement dated as of November 16, 2009 (as amended, the “Revolving Credit Facility”) and (ii) the Seventh Loan Modification Agreement amending certain terms of the Amended and Restated Export-Import Bank Loan and Security Agreement dated as of November 16, 2009 (as amended, the “Ex-Im Facility”). Pursuant to the terms of the Seventh Loan Modification Agreements, the Company and the Bank agreed to (i) extend the maturity date of the Revolving Credit Facility and the Ex-Im Facility to from October 29, 2013 to April 30, 2014, (ii) effective November 18, 2013 amend the definition of the Financial Covenant by deleting the requirement to maintain liquidity of at least $1.25 million at all times based on cash on hand and availability under the credit facility and replacing it with a newly defined covenant whereby the Company shall maintain cash on hand of at least $2.5 million at all times, as long as any commitment remains outstanding under the facilities, and (iii) amend the definition of Streamline Facility Eligible to increase the liquidity requirement from $2.5 million to $3.5 million. | |
The Company's obligations under these two credit facilities, as well as the guidance line, are secured by substantially all of the assets of the Company. Advances under the Revolving Credit Facility are limited to 80% of eligible receivables. Advances under the Ex-Im Facility are limited to (i) 90% of eligible receivables subject to a suitable foreign currency hedge agreement if applicable, plus (ii) 75% of all other eligible receivables billed in foreign currency, plus (iii) 50% of the value of eligible inventory, as defined. In addition, until all amounts under the credit facilities with the Bank are repaid, covenants under the credit facilities impose restrictions on the Company's ability to, among other things, incur additional indebtedness, create or permit liens on the Company's assets, merge, consolidate or dispose of assets (other than in the ordinary course of business), make dividend and other restricted payments, make certain debt or equity investments, make certain acquisitions, engage in certain transactions with affiliates or change the business conducted by the Company. Any failure by the Company to comply with the covenants and obligations under the credit facilities could result in an event of default, in which case the Bank may be entitled to declare all amounts owed to be due and payable immediately. | |
Under the credit facilities, interest on outstanding borrowings accrues at a rate per annum equal to the greater of (i) the prime rate plus 2.5% or (ii) 7.0%. In addition, if the Company achieves certain levels of liquidity, based on cash on hand and availability under the credit facility, the Company will have a 0.5% lower interest rate. | |
N2 Bio has has two separate agreements under one credit facility with Middlesex Savings Bank (“MSB”): (i) a Secured Term Loan and (ii) a Secured Revolving Demand Note. Under the Secured Term Loan, N2 Bio borrowed $6.0 million on September 18, 2013 to finance the purchase of the Bio Business Unit from the Company. The advance made under the Secured Term Loan will bear interest at a fixed rate of 4.5% per annum in eighty-four (84) consecutive monthly payments starting on October 18, 2013. If not sooner paid, the Secured Term Loan shall be due and payable in full on September 18, 2020. The Secured Revolving Demand Note provides an amount available of up to $1.0 million. Advances made under the Secured Revolving Demand Note will bear interest at MSB's prime rate, as determined, plus 0.5% per annum but in no event shall the interest rate be less than 3.75% per annum. The maturity date of the Secured Revolving Demand Note is September 18, 2014. | |
N2 Bio's obligations under the credit facility, is secured by substantially all of the assets of N2 Bio. Advances under the Secured Revolving Demand Note are limited to 75% of eligible receivables. In addition, until all amounts under the credit facilities with MSB are repaid, covenants under the credit facilities impose restrictions on the N2 Bio's ability to, among other things, incur additional indebtedness, create or permit liens on the N2 Bio's assets, merge, consolidate or dispose of assets (other than in the ordinary course of business), make dividend and other restricted payments, make certain debt or equity investments, make certain acquisitions, engage in certain transactions with affiliates or change the business conducted by the N2 Bio. Any failure by N2 Bio to comply with the covenants and obligations under the credit facilities could result in an event of default, in which case MSB may be entitled to declare all amounts owed to be due and payable immediately. | |
Advances outstanding under the Company's Revolving Credit Facility were $144 thousand and $449 thousand at September 30, 2013 and December 31, 2012, respectively. Advances outstanding under the Company's Ex-Im Facility were zero and $141 thousand at September 30, 2013 and December 31, 2012, respectively. Advances outstanding under the N2 Bio Secured Term Loan were $6.0 million at September 30, 2013. Advances outstanding under the N2 Bio Secured Revolving Demand Note were $437 thousand at September 30, 2013. As of September 30, 2013, the interest rate per annum on the Company's Revolving Credit Facility and Ex-Im Facility was 6.5% and 6.5%, respectively. The interest rate per annum on the N2 Bio Secured Term Loan and Secured Revolving Demand Note on September 30, 2013 was 4.5% and 3.75%, respectively. The Company had utilized $675 thousand of the guidance line at December 31, 2012. Combined availability under the Revolving Credit Facility, the Ex-Im Facility and the Secured Revolving Demand Note was $262 thousand as of September 30, 2013. |
Sharebased_Compensation
Share-based Compensation | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Stock based Compensation and Stock Option Plan [Abstract] | ' | |||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ' | |||||||||||||||
Share-Based Compensation | ||||||||||||||||
The Company has recognized share-based compensation expense from continuing operations of approximately $11 thousand and $48 thousand for the three months ended September 30, 2013 and 2012, respectively. The Company has recognized share-based compensation expense from continuing operations of approximately $88 thousand and $169 thousand for the nine months ended September 30, 2013 and 2012, respectively. The total non-cash, share-based compensation expense from continuing operations included in the unaudited condensed consolidated statements of operations for the periods presented is included in the following expense categories: | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
(in thousands) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Cost of contract research, services | $ | 1 | $ | 6 | $ | 11 | $ | 16 | ||||||||
Cost of goods sold | — | 6 | 7 | 31 | ||||||||||||
Administrative and selling | 10 | 36 | 70 | 122 | ||||||||||||
Total share-based compensation | $ | 11 | $ | 48 | $ | 88 | $ | 169 | ||||||||
There was no share-based compensation expense from discontinued operations for the three and nine months ended September 30, 2013. Share-based compensation expense from discontinued operations was zero and $(7) thousand for the three and nine months ended September 30, 2012, respectively. No share-based compensation expense was capitalized during the nine months ended September 30, 2013 and 2012. Compensation expense related to stock options to be charged in future periods amounts to approximately $27 thousand at September 30, 2013 and will be recognized over a weighted-average period of 0.83 years as follows: | ||||||||||||||||
For the years ended December 31, | Expected | |||||||||||||||
Compensation Expense | ||||||||||||||||
(in thousands) | ||||||||||||||||
2013 | $ | 8 | ||||||||||||||
2014 | 19 | |||||||||||||||
$ | 27 | |||||||||||||||
The Company estimates forfeitures at the time of grant and revises, if necessary, in subsequent periods if actual forfeitures differ from those estimates in order to derive the Company’s best estimate of awards ultimately expected to vest. Forfeitures represent only the unvested portion of a surrendered option and are typically estimated based on historical experience. | ||||||||||||||||
At September 30, 2013, the Company had outstanding options under two option plans: the 1996 Equity Incentive Plan (the “1996 Plan”) and the 2007 Stock Equity Plan (the “2007 Plan”, together the “Plans”). Both Plans were approved by stockholders and provided that the Board of Directors may grant options to purchase the Company’s common stock to key employees and directors of the Company. Incentive and non-qualified options must be granted at least at the fair market value of the common stock or, in the case of certain optionees, at 110% of such fair market value at the time of grant. The options may be exercised, subject to certain vesting requirements, for periods up to ten years from the date of issue. The 1996 Plan expired with respect to the issuance of new grants as of December 10, 2006. Accordingly, future grants may be made only under the 2007 Plan. | ||||||||||||||||
A summary of options outstanding under the Plans as of September 30, 2013 and changes during the nine-month period ended September 30, 2013 is as follows: | ||||||||||||||||
Number of Shares | Weighted-Average Exercise Price | Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value (in thousands) | |||||||||||||
Options Outstanding at December 31, 2012 | 644,446 | $ | 6.21 | |||||||||||||
Granted | 26,000 | $ | 0.48 | |||||||||||||
Exercised | — | $ | — | |||||||||||||
Cancelled/expired | (102,875 | ) | $ | 5.71 | ||||||||||||
Options outstanding at September 30, 2013 | 567,571 | $ | 6.04 | 5.38 | $ | 1 | ||||||||||
Options vested and exercisable at September 30, 2013 | 553,821 | $ | 6.08 | 5.34 | $ | 1 | ||||||||||
Option vested and expected to vest at September 30, 2013 | 567,096 | $ | 6.07 | 5.34 | $ | — | ||||||||||
Options available for future grant at September 30, 2013 | 438,434 | |||||||||||||||
The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $0.37 as of September 30, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. The total intrinsic value of options exercised was approximately zero and zero for the nine months ended September 30, 2013 and 2012, respectively. The total intrinsic value of options expected to vest at September 30, 2013 was approximately zero, and the weighted average remaining contractual life of outstanding options that are expected to vest is 5.28 years. | ||||||||||||||||
The per-share weighted-average fair value of stock options granted during the three and nine months ended September 30, 2013 was $0.26 and $0.55, respectively, and $0.48 and $1.29 for the three and nine months ended September 30, 2012, respectively, on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: | ||||||||||||||||
Year | Expected | Risk-Free | Expected | Expected | ||||||||||||
Dividend Yield | Interest Rate | Option Life | Volatility Factor | |||||||||||||
2013 | — | 1.40% | 5.1 years | 99.80% | ||||||||||||
2012 | — | 0.62% | 5.1 years | 92.10% | ||||||||||||
The risk free interest rate reflects treasury yields rates over a term that approximates the expected option life. The expected option life is calculated based on historical lives of all options issued under the Plans. The expected volatility factor is determined by measuring the actual stock price volatility over a term equal to the expected life of the options granted. |
Accumulated_Other_Comprehensiv
Accumulated Other Comprehensive Income (Notes) | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Accumulated Other Comprehensive Income [Abstract] | ' | ||||
Comprehensive Income (Loss) Note [Text Block] | ' | ||||
Accumulated Other Comprehensive Income | |||||
Changes in accumulated other comprehensive income balances by component for the nine months ended September 30, 2013 consist of the following: | |||||
(in thousands) | Unrealized Gains (Losses) on Available for Sale Securities | ||||
Balance, December 31, 2012 | $ | 222 | |||
Other comprehensive income before reclassification | 170 | ||||
Amounts reclassified from accumulated other comprehensive income | (65 | ) | |||
Net current-period other comprehensive income | 105 | ||||
Balance, September 30, 2013 | $ | 327 | |||
Reporting reclassifications out of accumulated other comprehensive income for the nine months ended September 30, 2013 consist of the following: | |||||
Details about Accumulated Other Comprehensive Income Components | Amount Reclassified from Accumulated Other Comprehensive Income (in thousands) | Affected Line Item in the Statement Where Net Income is Resented | |||
Unrealized gains (losses) on available-for-sale investments | $ | (65 | ) | Selling, general and administrative expenses |
Discontinued_Operations_and_As
Discontinued Operations and Assets Held for Sale | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Discontinued Operations and Assets Held for Sale [Abstract] | ' | |||||||||||||||
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | ' | |||||||||||||||
Discontinued Operations and Assets Held for Sale | ||||||||||||||||
The accompanying unaudited condensed consolidated balance sheets, statements of operations and cash flows present the results of operations and assets and liabilities of the Semiconductor Business Unit and the liabilities of the Medical Products Business Unit as discontinued operations. | ||||||||||||||||
Sales of Medical Products Business Unit | ||||||||||||||||
On December 14, 2009, the Company completed the sale of its medical products business unit, which developed and marketed coated and uncoated hemodialysis catheters and related devices for the treatment of chronic kidney disease (the “Medical Products Business Unit”), to Bard Access Systems, Inc. (“Bard”). Accordingly, the liabilities of the Medical Products Business Unit are being presented herein as discontinued operations. | ||||||||||||||||
The Company recorded a loss from discontinued operations before the sale of the Medical Products Business Unit of zero and $250 thousand for the nine months ended September 30, 2013 and 2012, respectively. | ||||||||||||||||
Sale of Semiconductor Business Unit | ||||||||||||||||
During the first quarter of 2012, the Company began pursuing an exclusive sales process of the Company's Semiconductor Business Unit. The Company (i) determined that the Semiconductor Business Unit was a separate component of the Company's business as, historically, management reviewed separately the Semiconductor Business Unit's financial results apart from the Company's ongoing continuing operations, (ii) eliminated the Semiconductor Business Unit's financial results from ongoing operations and (iii) determined that the Company will have no further continuing involvement in the operations of the Semiconductor Business Unit or cash flows from the Semiconductor Business Unit after the sale. | ||||||||||||||||
On March 9, 2012, the Company completed the sale of the Semiconductor Business Unit to Masimo. The asset purchase agreement provided that the aggregate purchase price for the Semiconductor Business Unit was $8.0 million plus the assumption of $500 thousand in liabilities, with the cash portion of the purchase price being reduced by retained cash, accounts receivable and liabilities assumed by Masimo in excess of the agreed upon assumed liabilities. As a result, in the first quarter of 2012 the Company received approximately $7.3 million in cash (less the escrow described below) and incurred legal and transaction related fees of $425 thousand and Masimo assumed approximately $1.2 million in liabilities. Of the purchase price, approximately $718 thousand was deposited into an indemnity escrow account for fifteen months to partially secure the Company's obligations for any indemnity claims under the asset purchase agreement. There were no indemnity claims related to the asset purchase agreement and the Company received full payment from the indemnity escrow account in June 2013. In connection with this transaction, the lease for the premises in Hudson, New Hampshire where the Semiconductor Business Unit was located, was terminated on March 9, 2012, and the Company was released from all future obligations under the lease as of such date. | ||||||||||||||||
The Company recorded a loss from discontinued operations before the sale of the Semiconductor Business Unit of zero and $430 thousand for the nine months ended September 30, 2013 and 2012, respectively. | ||||||||||||||||
Summarized Financial Information of the Discontinued Operations | ||||||||||||||||
The assets and liabilities of the Semiconductor Business Unit and the liabilities of the Medical Products Business Unit as of September 30, 2013 and December 31, 2012 are as follows: | ||||||||||||||||
(in thousands) | September 30, 2013 | December 31, 2012 | ||||||||||||||
Assets of Discontinued Operations | ||||||||||||||||
Current Assets | ||||||||||||||||
Restricted cash | $ | — | $ | 718 | ||||||||||||
Total current assets of discontinued operations | — | 718 | ||||||||||||||
Total assets of discontinued operations | $ | — | $ | 718 | ||||||||||||
Liabilities of Discontinued Operations | ||||||||||||||||
Current liabilities of discontinued operations | ||||||||||||||||
Accrued liabilities | $ | 21 | $ | 171 | ||||||||||||
Total current liabilities of discontinued operations | 21 | 171 | ||||||||||||||
Total liabilities of discontinued operations | $ | 21 | $ | 171 | ||||||||||||
Condensed results of operations relating to the Medical Products Business Unit for the three months ended September 30, 2013 and 2012 and condensed results of operations relating to the Medical Products Business Unit and the Semiconductor Business Unit for the nine months ended September 30, 2013 and 2012 are as follows: | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
(in thousands) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Net sales and revenues | $ | — | $ | — | $ | — | $ | 425 | ||||||||
Gross margin | $ | — | $ | — | $ | — | $ | (296 | ) | |||||||
Loss from discontinued operations before sale of business unit | $ | — | $ | (250 | ) | $ | — | $ | (680 | ) | ||||||
Gain on sale of business unit, net of transaction expenses | — | — | — | 5,449 | ||||||||||||
Income tax provision | — | — | — | (2,008 | ) | |||||||||||
Net income from discontinued operations, net of tax | $ | — | $ | (250 | ) | $ | — | $ | 2,761 | |||||||
Subsequent_Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
Subsequent Events | |
The Company evaluated subsequent events through the date of this filing. Except for the Seventh Loan Modification Agreement as disclosed in Note 10, there are no subsequent events to report. |
Variable_Interest_Entity_Notes
Variable Interest Entity (Notes) | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Noncontrolling Interest [Line Items] | ' | |||
Consolidation, Variable Interest Entity, Policy [Policy Text Block] | ' | |||
Variable Interest Entity | ||||
The Company has interests in N2 Bio which is a VIE. If the Company is the primary beneficiary of a VIE, the Company is required to consolidate it. To determine if the Company is the primary beneficiary, the Company evaluates whether the Company has the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company's evaluation includes identification of significant activities and an assessment of the Company's ability to direct those activities based on governance provisions and arrangements to provide or receive product and process technology, product supply, operations services, equity funding, financing and other applicable agreements and circumstances. The Company's assessments of whether the Company is the primary beneficiary of its VIE require significant assumptions and judgments. | ||||
On September 18, 2013, the Company, Spire Biomedical, Inc. (the “Subsidiary” and together with the Company, “Spire Bio”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with N2 Biomedical LLC (“N2 Bio”) pursuant to which N2 Bio agreed to (i) acquire substantially all of the assets of Spire Bio's biomedical business (the “Bio Business Unit”) and (ii) assume and pay certain liabilities related to the purchased assets as set forth in the Purchase Agreement (collectively, the “Transaction”). The Transaction closed on September 18, 2013. The purchase price for the Bio Business Unit was $10.5 million plus the assumption of liabilities of approximately $100 thousand, with $6.0 million paid in cash at closing, a $2.4 million subordinated convertible promissory note, and 310,549 Series A Convertible Preferred Units of N2 Bio valued at approximately $2.1 million ($6.72 per share). The difference between the consideration paid and the carrying value of the assets and liabilities acquired by N2 Bio was recorded as a deemed dividend to the Company in the amount of $9.5 million and has been eliminated in consolidation. Mark C. Little was the Chief Executive Officer of the Subsidiary, is a director of the Company and is the Chief Executive Officer of N2 Bio. Mark C. Little is the son of Roger G. Little, Chief Executive Officer of the Company. | ||||
On September 18, 2013, N2 Bio entered into a Lease Agreement (the “N2 Bio Bedford Lease”) with SPI-Trust with respect to 27 thousand square feet of space which represents approximately 19% of space in the Bedford, Massachusetts premises. The term of the N2 Bio Bedford Lease commenced on September 18, 2013 and is set to expire on November 30, 2020. The annual rental rate prorated for September 18, 2013 to November 30, 2013 is $16.00 per square foot on a triple net basis, whereby the tenant is responsible for operating expenses, taxes and maintenance of the building. The annual rental rate increases on December 1, 2013 and each anniversary thereafter by $0.50 per square foot. | ||||
The Company has determined that N2 Bio is a VIE because the equity investment at risk from the majority shareholders of N2 Bio is not sufficient to permit N2 Bio to finance its activities without additional subordinated financial support from the Company. As discussed above, N2 Bio is subject to a subordinated convertible promissory note. Additionally, Mark Little is the Chief Executive Officer of N2 Bio and also a director of the Company which qualifies as a related party. The Company has also determined that the Company has the obligation to absorb losses and the right to receive benefits from N2 Bio that could potentially be significant to it. Therefore, the Company has determined that N2 Bio is a VIE and must consolidate the financial condition, results of operations and cash flows of N2 Bio with those of its own. | ||||
The assets and liabilities with carryover basis as noted above from the VIE included in the condensed consolidated balance sheets as of September 30, 2013 are as follows: | ||||
(in thousands) | September 30, 2013 | |||
Assets of VIE | ||||
Current Assets | ||||
Cash and cash equivalents | $ | 276 | ||
Accounts receivable trade, net | 753 | |||
Inventories, net | 111 | |||
Prepaid expenses and other current assets | 71 | |||
Total current assets of VIE | 1,211 | |||
Property and equipment, net | 211 | |||
Intangible & other assets, net | 88 | |||
Total assets of VIE | $ | 1,510 | ||
Liabilities of VIE | ||||
Current liabilities | ||||
Current portion of term loan | $ | 744 | ||
Revolving line of credit | 438 | |||
Accounts payable | 91 | |||
Due to related parties | 4 | |||
Accrued liabilities | 197 | |||
Total current liabilities of VIE | 1,474 | |||
Long-term portion of term loan | 5,255 | |||
Long-term note payable to related party | 2,400 | |||
Total liabilities of VIE | $ | 9,129 | ||
Accounts_ReceivableAdvances_on1
Accounts Receivable/Advances on Contracts in Progress (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Accounts Receivable and Advances on Contracts in Progress [Abstract] | ' | |||||||
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | ' | |||||||
Net accounts receivable, trade and advances on contracts in progress consists of the following: | ||||||||
(in thousands) | September 30, 2013 | December 31, 2012 | ||||||
Amounts billed | $ | 1,365 | $ | 1,927 | ||||
Accrued revenue | 18 | 238 | ||||||
Gross accounts receivable - trade | 1,383 | 2,165 | ||||||
Less: Allowance for doubtful accounts | (20 | ) | (28 | ) | ||||
Net accounts receivable - trade | $ | 1,363 | $ | 2,137 | ||||
Advances on contracts in progress | $ | 1,046 | $ | 1,037 | ||||
Inventories_and_Deferred_Costs1
Inventories and Deferred Costs of Goods Sold (Tables) | 9 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventories and Deferred Costs of Goods Sold [Abstract] | ' | |||||||
Schedule of Inventories and Deferred Costs of Goods Sold [Table Text Block] | ' | |||||||
Inventories, net of $1.1 million and $860 thousand of reserves at September 30, 2013 and December 31, 2012, respectively, and deferred cost of goods sold consist of the following at: | ||||||||
(in thousands) | September 30, | December 31, | ||||||
2013 | 2012 | |||||||
Raw materials | $ | 1,489 | $ | 1,784 | ||||
Work in process | 1,923 | 2,103 | ||||||
Finished goods | 1,244 | 1,429 | ||||||
Net inventory | $ | 4,656 | $ | 5,316 | ||||
Deferred cost of goods sold | $ | 92 | $ | 185 | ||||
Income_loss_Per_Share_Tables
Income (loss) Per Share (Tables) | 9 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Income (loss) Per Share [Abstract] | ' | |||||||||||
Schedule of Weighted Average Number of Shares [Table Text Block] | ' | |||||||||||
The following table provides a reconciliation of the denominators of the Company’s reported basic and diluted income (loss) per share computations for the periods ended: | ||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||
Weighted average number of common and common equivalent shares outstanding – basic | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 | ||||||||
Add: Net additional common shares upon assumed exercise of common stock options | — | — | — | — | ||||||||
Adjusted weighted average number of common and common equivalents shares outstanding – diluted | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 | ||||||||
Operating_Segments_and_Related1
Operating Segments and Related Information (Tables) | 9 Months Ended | |||||||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||||||
Operating Segments and Related Information [Abstract] | ' | |||||||||||||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | ' | |||||||||||||||||||||||||||
The following table presents certain continuing operating division information in accordance with the provisions of ASC 280, Segments Reporting. | ||||||||||||||||||||||||||||
(in thousands) | Solar | Biomedical | Consolidated | |||||||||||||||||||||||||
For the three months ended September 30, 2013 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 2,445 | $ | 1,709 | 4,154 | |||||||||||||||||||||||
Operating loss from continuing operations | $ | (1,462 | ) | $ | (749 | ) | (2,211 | ) | ||||||||||||||||||||
For the three months ended September 30, 2012 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 2,485 | $ | 1,743 | 4,228 | |||||||||||||||||||||||
Operating income (loss) from continuing operations | $ | (2,197 | ) | $ | 179 | (2,018 | ) | |||||||||||||||||||||
For the nine months ended September 30, 2013 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 5,783 | $ | 5,183 | $ | 10,966 | ||||||||||||||||||||||
Operating loss from continuing operations | $ | (6,192 | ) | $ | (389 | ) | $ | (6,581 | ) | |||||||||||||||||||
For the nine months ended September 30, 2012 | ||||||||||||||||||||||||||||
Net sales and revenues | $ | 13,219 | $ | 5,104 | $ | 18,323 | ||||||||||||||||||||||
Operating income (loss) from continuing operations | $ | (5,740 | ) | $ | 326 | $ | (5,414 | ) | ||||||||||||||||||||
Revenues By Geography [Table Text Block] | ' | |||||||||||||||||||||||||||
The following table shows net sales and revenues by geographic area (based on customer location): | ||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||
(in thousands) | 2013 | % | 2012 | % | 2013 | % | 2012 | % | ||||||||||||||||||||
United States | $ | 3,042 | 73 | % | $ | 3,005 | 71 | % | $ | 7,576 | 69 | % | $ | 7,955 | 43 | % | ||||||||||||
Europe/Africa | 874 | 21 | 376 | 9 | 1,664 | 15 | 3,062 | 17 | ||||||||||||||||||||
Asia | 238 | 6 | 839 | 20 | 1,509 | 14 | 7,246 | 40 | ||||||||||||||||||||
Rest of the world | — | — | 8 | — | 217 | 2 | 60 | — | ||||||||||||||||||||
$ | 4,154 | 100 | % | $ | 4,228 | 100 | % | $ | 10,966 | 100 | % | $ | 18,323 | 100 | % | |||||||||||||
Intangible_and_Other_Assets_Ta
Intangible and Other Assets (Tables) | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Intangible and Other Assets [Abstract] | ' | ||||
Schedule of Expected Amortization Expense [Table Text Block] | ' | ||||
For disclosure purposes, the table below includes future amortization expense for patents and licenses owned by the Company as well as estimated amortization expense related to patents that remain pending at September 30, 2013 of $117 thousand. This estimated expense for patents pending assumes that the patents are issued immediately, and therefore are being amortized over five years on a straight-line basis. Estimated amortization expense for the periods ending December 31, is as follows: | |||||
(in thousands) | Amortization Expense | ||||
2013 remaining 3 months | $ | 21 | |||
2014 | 69 | ||||
2015 | 50 | ||||
2016 | 28 | ||||
2017 | 28 | ||||
2018 | 23 | ||||
Thereafter | 28 | ||||
$ | 247 | ||||
Fair_Value_Measurements_Fair_V
Fair Value Measurements Fair Value Measurements (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Fair Value Measurements [Abstract] | ' | |||||||||||||||
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | ' | |||||||||||||||
The following table presents the financial instruments related to the Company’s available-for-sale investment carried at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 by ASC 820-10 valuation hierarchy (as defined above). | ||||||||||||||||
(in thousands) | Balance as of | Level 1 | Level 2 | Level 3 | ||||||||||||
30-Sep-13 | ||||||||||||||||
Cash and short term investments | $ | 87 | $ | 87 | $ | — | $ | — | ||||||||
Common stock | ||||||||||||||||
Basic Materials | 22 | 22 | — | — | ||||||||||||
Consumer Goods | 143 | 143 | — | — | ||||||||||||
Energy | 120 | 120 | — | — | ||||||||||||
Financial | 149 | 149 | — | — | ||||||||||||
Healthcare | 138 | 138 | — | — | ||||||||||||
Industrial Goods | 158 | 158 | — | — | ||||||||||||
Services | 34 | 34 | — | — | ||||||||||||
Technology | 464 | 464 | — | — | ||||||||||||
Transportation | — | — | — | — | ||||||||||||
Utilities | 14 | 14 | — | — | ||||||||||||
Total Common Stock | 1,242 | 1,242 | — | — | ||||||||||||
Mutual Fund | ||||||||||||||||
Diversified Emerging Markets | 289 | — | 289 | — | ||||||||||||
Foreign Large Blend | 265 | — | 265 | — | ||||||||||||
Foreign Large Growth | 273 | — | 273 | — | ||||||||||||
Large Growth | 250 | — | 250 | — | ||||||||||||
Small Blend | 293 | 293 | — | — | ||||||||||||
Global High Yield Income Fund | 56 | — | 56 | — | ||||||||||||
Total Mutual Fund | 1,426 | 293 | 1,133 | — | ||||||||||||
Fixed Income | ||||||||||||||||
Domestic | 421 | — | 421 | — | ||||||||||||
International | 49 | — | 49 | — | ||||||||||||
Total Fixed Income | 470 | — | 470 | — | ||||||||||||
Total available-for-sale investments (1) | $ | 3,225 | $ | 1,622 | $ | 1,603 | $ | — | ||||||||
Percent of total | 100 | % | 50 | % | 50 | % | — | % | ||||||||
(in thousands) | Balance as of December 31, 2012 | Level 1 | Level 2 | Level 3 | ||||||||||||
Cash and short term investments | $ | 32 | $ | 32 | $ | — | $ | — | ||||||||
Common Stock | ||||||||||||||||
Basic Materials | 15 | 15 | — | — | ||||||||||||
Consumer Goods | 58 | 58 | — | — | ||||||||||||
Energy | 29 | 29 | — | — | ||||||||||||
Financial | 61 | 61 | — | — | ||||||||||||
Healthcare | 52 | 52 | — | — | ||||||||||||
Industrial Goods | 51 | 51 | — | — | ||||||||||||
Services | 32 | 32 | — | — | ||||||||||||
Technology | 376 | 376 | — | — | ||||||||||||
Transportation | 8 | 8 | — | — | ||||||||||||
Utilities | 26 | 26 | — | — | ||||||||||||
Total Common Stock | 708 | 708 | — | — | ||||||||||||
Mutual Fund | ||||||||||||||||
Diversified Emerging Markets | 187 | — | 187 | — | ||||||||||||
Precious Metals Fund | 49 | — | 49 | — | ||||||||||||
Foreign Large Blend | 244 | — | 244 | — | ||||||||||||
Foreign Large Growth | 250 | — | 250 | — | ||||||||||||
Large Growth | 220 | — | 220 | — | ||||||||||||
Small Blend Total | 525 | 525 | — | — | ||||||||||||
Global High Yield Income Fund | 52 | — | 52 | — | ||||||||||||
Total Mutual Funds | 1,527 | 525 | 1,002 | — | ||||||||||||
Fixed Income | ||||||||||||||||
Domestic | 678 | — | 678 | — | ||||||||||||
International | 18 | — | 18 | — | ||||||||||||
Total Fixed Income | 696 | — | 696 | — | ||||||||||||
Total available for-sale-investments (1) | $ | 2,963 | $ | 1,265 | $ | 1,698 | $ | — | ||||||||
Percent of total | 100 | % | 43 | % | 57 | % | — | % | ||||||||
(1) | Changes in the fair value of available-for-sale investments are recorded in accumulated other comprehensive income, a component of stockholders’ equity, in the Company’s unaudited condensed consolidated balance sheets. |
Sharebased_Compensation_Tables
Share-based Compensation (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Stock based Compensation and Stock Option Plan [Abstract] | ' | |||||||||||||||
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] | ' | |||||||||||||||
The Company has recognized share-based compensation expense from continuing operations of approximately $88 thousand and $169 thousand for the nine months ended September 30, 2013 and 2012, respectively. The total non-cash, share-based compensation expense from continuing operations included in the unaudited condensed consolidated statements of operations for the periods presented is included in the following expense categories: | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
(in thousands) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Cost of contract research, services | $ | 1 | $ | 6 | $ | 11 | $ | 16 | ||||||||
Cost of goods sold | — | 6 | 7 | 31 | ||||||||||||
Administrative and selling | 10 | 36 | 70 | 122 | ||||||||||||
Total share-based compensation | $ | 11 | $ | 48 | $ | 88 | $ | 169 | ||||||||
There was no share-based compensation expense from discontinued operations for the three and nine months ended September 30, 2013. Share-based compensation expense from discontinued operations was zero and $(7) thousand for the three and nine months ended September 30, 2012, respectively. No share-based compensation expense was capitalized during the nine months ended September 30, 2013 and 2012. Compensation expense related to stock options to be charged in future periods amounts to approximately $27 thousand at September 30, 2013 and will be recognized over a weighted-average period of 0.83 years as follows: | ||||||||||||||||
For the years ended December 31, | Expected | |||||||||||||||
Compensation Expense | ||||||||||||||||
(in thousands) | ||||||||||||||||
2013 | $ | 8 | ||||||||||||||
2014 | 19 | |||||||||||||||
$ | 27 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | ' | |||||||||||||||
A summary of options outstanding under the Plans as of September 30, 2013 and changes during the nine-month period ended September 30, 2013 is as follows: | ||||||||||||||||
Number of Shares | Weighted-Average Exercise Price | Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value (in thousands) | |||||||||||||
Options Outstanding at December 31, 2012 | 644,446 | $ | 6.21 | |||||||||||||
Granted | 26,000 | $ | 0.48 | |||||||||||||
Exercised | — | $ | — | |||||||||||||
Cancelled/expired | (102,875 | ) | $ | 5.71 | ||||||||||||
Options outstanding at September 30, 2013 | 567,571 | $ | 6.04 | 5.38 | $ | 1 | ||||||||||
Options vested and exercisable at September 30, 2013 | 553,821 | $ | 6.08 | 5.34 | $ | 1 | ||||||||||
Option vested and expected to vest at September 30, 2013 | 567,096 | $ | 6.07 | 5.34 | $ | — | ||||||||||
Options available for future grant at September 30, 2013 | 438,434 | |||||||||||||||
Accumulated_Other_Comprehensiv1
Accumulated Other Comprehensive Income Changes in accumulated other comprehensive income (Tables) | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Other Comprehensive Income [Abstract] | ' | |||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ' | |||
Changes in accumulated other comprehensive income balances by component for the nine months ended September 30, 2013 consist of the following: | ||||
(in thousands) | Unrealized Gains (Losses) on Available for Sale Securities | |||
Balance, December 31, 2012 | $ | 222 | ||
Other comprehensive income before reclassification | 170 | |||
Amounts reclassified from accumulated other comprehensive income | (65 | ) | ||
Net current-period other comprehensive income | 105 | |||
Balance, September 30, 2013 | $ | 327 | ||
Accumulated_Other_Comprehensiv2
Accumulated Other Comprehensive Income Reclassification Out of Accumulated Other Comprehensive Income (Tables) | 9 Months Ended | ||||
Sep. 30, 2013 | |||||
Reclassifications Out of Accumulated Other Comprehensive Incme [Abstract] | ' | ||||
Reclassification Out Of Accumulated Other Comprehensive Income [Table Text Block] | ' | ||||
Reporting reclassifications out of accumulated other comprehensive income for the nine months ended September 30, 2013 consist of the following: | |||||
Details about Accumulated Other Comprehensive Income Components | Amount Reclassified from Accumulated Other Comprehensive Income (in thousands) | Affected Line Item in the Statement Where Net Income is Resented | |||
Unrealized gains (losses) on available-for-sale investments | $ | (65 | ) | Selling, general and administrative expenses |
Discontinued_Operations_and_As1
Discontinued Operations and Assets Held for Sale (Tables) | 9 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Discontinued Operations and Assets Held for Sale [Abstract] | ' | |||||||||||||||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] | ' | |||||||||||||||
The assets and liabilities of the Semiconductor Business Unit and the liabilities of the Medical Products Business Unit as of September 30, 2013 and December 31, 2012 are as follows: | ||||||||||||||||
(in thousands) | September 30, 2013 | December 31, 2012 | ||||||||||||||
Assets of Discontinued Operations | ||||||||||||||||
Current Assets | ||||||||||||||||
Restricted cash | $ | — | $ | 718 | ||||||||||||
Total current assets of discontinued operations | — | 718 | ||||||||||||||
Total assets of discontinued operations | $ | — | $ | 718 | ||||||||||||
Liabilities of Discontinued Operations | ||||||||||||||||
Current liabilities of discontinued operations | ||||||||||||||||
Accrued liabilities | $ | 21 | $ | 171 | ||||||||||||
Total current liabilities of discontinued operations | 21 | 171 | ||||||||||||||
Total liabilities of discontinued operations | $ | 21 | $ | 171 | ||||||||||||
Condensed results of operations relating to the Medical Products Business Unit for the three months ended September 30, 2013 and 2012 and condensed results of operations relating to the Medical Products Business Unit and the Semiconductor Business Unit for the nine months ended September 30, 2013 and 2012 are as follows: | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
(in thousands) | 2013 | 2012 | 2013 | 2012 | ||||||||||||
Net sales and revenues | $ | — | $ | — | $ | — | $ | 425 | ||||||||
Gross margin | $ | — | $ | — | $ | — | $ | (296 | ) | |||||||
Loss from discontinued operations before sale of business unit | $ | — | $ | (250 | ) | $ | — | $ | (680 | ) | ||||||
Gain on sale of business unit, net of transaction expenses | — | — | — | 5,449 | ||||||||||||
Income tax provision | — | — | — | (2,008 | ) | |||||||||||
Net income from discontinued operations, net of tax | $ | — | $ | (250 | ) | $ | — | $ | 2,761 | |||||||
Variable_Interest_Entity_Table
Variable Interest Entity (Tables) | 9 Months Ended | |||
Sep. 30, 2013 | ||||
Noncontrolling Interest [Line Items] | ' | |||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | ' | |||
The assets and liabilities with carryover basis as noted above from the VIE included in the condensed consolidated balance sheets as of September 30, 2013 are as follows: | ||||
(in thousands) | September 30, 2013 | |||
Assets of VIE | ||||
Current Assets | ||||
Cash and cash equivalents | $ | 276 | ||
Accounts receivable trade, net | 753 | |||
Inventories, net | 111 | |||
Prepaid expenses and other current assets | 71 | |||
Total current assets of VIE | 1,211 | |||
Property and equipment, net | 211 | |||
Intangible & other assets, net | 88 | |||
Total assets of VIE | $ | 1,510 | ||
Liabilities of VIE | ||||
Current liabilities | ||||
Current portion of term loan | $ | 744 | ||
Revolving line of credit | 438 | |||
Accounts payable | 91 | |||
Due to related parties | 4 | |||
Accrued liabilities | 197 | |||
Total current liabilities of VIE | 1,474 | |||
Long-term portion of term loan | 5,255 | |||
Long-term note payable to related party | 2,400 | |||
Total liabilities of VIE | $ | 9,129 | ||
Description_of_Business_Detail
Description of Business (Details) (USD $) | 0 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | |||||||||
Apr. 30, 2014 | Oct. 29, 2013 | Sep. 18, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2011 | Sep. 18, 2013 | Sep. 30, 2013 | Mar. 09, 2012 | Mar. 31, 2012 | Dec. 14, 2009 | Sep. 18, 2014 | Sep. 30, 2013 | Sep. 18, 2013 | Sep. 30, 2013 | |
factories | factories | Biomedical Service [Member] | Biomedical Service [Member] | Semiconductor Business Unit [Member] | Semiconductor Business Unit [Member] | Medical Products Business Unit [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | Convertible Debt [Member] | ||||||||
countries | countries | sqft | Biomedical Service [Member] | |||||||||||||||
Number of Factories Which the Company's Equipment Has Been Installed | ' | ' | ' | 200 | ' | 200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Countries Which the Company's equipment has been installed | ' | ' | ' | 50 | ' | 50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Divestiture, Sale Price | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10,500,000 | ' | $8,000,000 | ' | ' | ' | ' | ' | ' |
Business Divestiture, Sale Price Allocation, Liabilities Assume | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | 500,000 | 1,200,000 | ' | ' | ' | ' | ' |
Proceeds from Divestiture of Businesses | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,000,000 | ' | 7,300,000 | ' | ' | ' | ' | ' |
Noncash or Part Noncash Divestiture, Amount of Consideration Received | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,400,000 |
Preferred Stock, Value, Issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,100,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Shares Outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | 310,549 | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Par or Stated Value Per Share | ' | ' | ' | ' | ' | ' | ' | ' | ' | $6.72 | ' | ' | ' | ' | ' | ' | $6.72 | ' |
Deemed dividend | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,500,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Receivable with Imputed Interest, Effective Yield (Interest Rate) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9.00% |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | ' | ' | 19.90% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cost of shared services | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reduce lease space | ' | ' | 19.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Area of Real Estate Property | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,000 | ' |
rent per square foot for first year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16 | ' |
Rental rate increase on each annual anniversary | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.5 | ' |
Disposal Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18-Sep-13 | ' | 9-Mar-12 | ' | 14-Dec-09 | ' | ' | ' | ' |
Export Sales, Percentage | ' | ' | ' | 27.00% | 29.00% | 31.00% | 57.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Income (Loss) from continuing operations | ' | ' | ' | -2,211,000 | -2,018,000 | -6,581,000 | -5,414,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net cash provided by operating activities of discontinued operations | ' | ' | ' | ' | ' | -150,000 | -1,726,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Cash Provided by (Used in) Operating Activities | ' | ' | ' | ' | ' | -3,702,000 | -6,265,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash and Cash Equivalents | ' | ' | ' | $5,897,000 | $5,178,000 | $5,897,000 | $5,178,000 | $3,030,000 | $4,758,000 | ' | ' | ' | ' | ' | ' | $276,000 | ' | ' |
Line of Credit Facility, Expiration Date | 30-Apr-14 | 29-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18-Sep-14 | ' | ' | ' |
Interim_Financial_Statements_D
Interim Financial Statements (Details) | 0 Months Ended | ||
Mar. 09, 2012 | Dec. 14, 2009 | Sep. 18, 2013 | |
Semiconductor Business Unit [Member] | Medical Products Business Unit [Member] | Biomedical Service [Member] | |
Disposal Date | 9-Mar-12 | 14-Dec-09 | 18-Sep-13 |
Accounts_ReceivableAdvances_on2
Accounts Receivable/Advances on Contracts in Progress (Details) (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' | ' |
Amounts billed | $1,365 | ' | $1,927 |
Accrued revenue | 18 | ' | 238 |
Accounts Receivable, Gross | 1,383 | ' | 2,165 |
Less: Allowance for doubtful accounts | -20 | ' | -28 |
Net accounts receivable - trade | 1,363 | ' | 2,137 |
Allowance for Doubtful Accounts Receivable, Recoveries | 24 | 10 | ' |
Customer Advances, Current | $1,046 | ' | $1,037 |
Inventories_and_Deferred_Costs2
Inventories and Deferred Costs of Goods Sold (Details) (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 |
Raw materials | $1,489 | ' | $1,784 |
Work in process | 1,923 | ' | 2,103 |
Finished goods | 1,244 | ' | 1,429 |
Net inventory | 4,656 | ' | 5,316 |
Inventory Valuation Reserves | 1,100 | ' | 860 |
Deferred cost of goods sold | 92 | ' | 185 |
Inventory write-off | $0 | $29 | ' |
Income_loss_Per_Share_Details
Income (loss) Per Share (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Weighted average number of common and common equivalent shares outstanding – basic | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 |
Add: Net additional common shares upon assumed exercise of common stock options | 0 | 0 | 0 | 0 |
Adjusted weighted average number of common and common equivalents shares outstanding - diluted | 9,207,874 | 8,562,633 | 9,165,844 | 8,562,633 |
In Money Stock Options [Member] | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,152 | 220 | 3,708 | 1,335 |
Underwater Stock Options [Member] | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 559,571 | 629,446 | 535,571 | 619,446 |
Operating_Segments_and_Related2
Operating Segments and Related Information Sales and Revenue by Segment (Details) (USD $) | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | |||||||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Mar. 09, 2012 | Dec. 14, 2009 |
Solar [Member] | Solar [Member] | Solar [Member] | Solar [Member] | Biomedical [Member] | Biomedical [Member] | Biomedical [Member] | Biomedical [Member] | Semiconductor Business Unit [Member] | Medical Products Business Unit [Member] | |||||
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Disposal Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9-Mar-12 | 14-Dec-09 |
Revenues | $4,154 | $4,228 | $10,966 | $18,323 | $2,445 | $2,485 | $5,783 | $13,219 | $1,709 | $1,743 | $5,183 | $5,104 | ' | ' |
Operating Income (Loss) from continuing operations | ($2,211) | ($2,018) | ($6,581) | ($5,414) | ($1,462) | ($2,197) | ($6,192) | ($5,740) | ($749) | $179 | ($389) | $326 | ' | ' |
Operating_Segments_and_Related3
Operating Segments and Related Information Net Sales and Revenues by Geographic Area (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Revenues | $4,154 | $4,228 | $10,966 | $18,323 |
Revenue, Percentage | 100.00% | 100.00% | 100.00% | 100.00% |
United States [Member] | ' | ' | ' | ' |
Revenues | 3,042 | 3,005 | 7,576 | 7,955 |
Revenue, Percentage | 73.00% | 71.00% | 69.00% | 43.00% |
Europe / Africa [Member] | ' | ' | ' | ' |
Revenues | 874 | 376 | 1,664 | 3,062 |
Revenue, Percentage | 21.00% | 9.00% | 15.00% | 17.00% |
Asia [Member] | ' | ' | ' | ' |
Revenues | 238 | 839 | 1,509 | 7,246 |
Revenue, Percentage | 6.00% | 20.00% | 14.00% | 40.00% |
Rest of the World [Member] | ' | ' | ' | ' |
Revenues | $0 | $8 | $217 | $60 |
Revenue, Percentage | 0.00% | 0.00% | 2.00% | 0.00% |
Operating_Segments_and_Related4
Operating Segments and Related Information Narrative Revenue (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Government Contracts | '61 | '392 | '704 | '1264 |
Government Contracts Concentration Risk [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 1.00% | 9.00% | 6.00% | 7.00% |
Solar Equipment [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
The Number of Major Customers That Account for 10% or Greater of the Company's Revenue | 1 | ' | ' | 2 |
Solar Equipment [Member] | Customer E [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 13.00% | ' | ' | ' |
Solar Equipment [Member] | Customer J [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | ' | ' | ' | 12.00% |
Solar Equipment [Member] | Customer K [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | ' | ' | ' | 10.00% |
Solar equipment research and developement [Domain] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
The Number of Major Customers That Account for 10% or Greater of the Company's Revenue | 1 | ' | ' | ' |
Solar equipment research and developement [Domain] | Customer D [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 14.00% | ' | ' | ' |
Solar Photovoltaic System [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
The Number of Major Customers That Account for 10% or Greater of the Company's Revenue | 1 | ' | ' | ' |
Solar Photovoltaic System [Member] | Customer F [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 15.00% | ' | ' | ' |
Biomedical Service [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
The Number of Major Customers That Account for 10% or Greater of the Company's Revenue | 1 | 1 | 2 | 1 |
Biomedical Service [Member] | Customer A [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | ' | ' | 11.00% | ' |
Biomedical Service [Member] | Customer C [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Concentration Risk, Percentage | 17.00% | 19.00% | 20.00% | 12.00% |
Operating_Segments_and_Related5
Operating Segments and Related Information Narrative Accounts Receivable (Details) | Sep. 30, 2013 | Dec. 31, 2012 |
customers | customers | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
The Number Of Customers That Account for 10% or Greater of the Company's Accounts Receivables | 3 | 1 |
Customer A [Member] | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Percentage Of Total Trade Receivables | 17.00% | ' |
Customer D [Member] | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Percentage Of Total Trade Receivables | 20.00% | ' |
Customer C [Member] | ' | ' |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ' | ' |
Percentage Of Total Trade Receivables | 25.00% | 24.00% |
Intangible_and_Other_Assets_In
Intangible and Other Assets Intangible Asset Narrative (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||||||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 |
Patents [Member] | Patents [Member] | Licenses [Member] | Licenses [Member] | |||||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Finite-Lived Intangible Assets, Net | $247 | ' | $247 | ' | $74 | $111 | $56 | $60 |
Finite-Lived Intangible Assets, Accumulated Amortization | ' | ' | ' | ' | 859 | 822 | 19 | 15 |
Amortization of Intangible Assets | 14 | 44 | 41 | 84 | ' | ' | ' | ' |
Pending Patent | $117 | ' | $117 | ' | ' | ' | ' | ' |
Finite-Lived Intangible Asset, Useful Life | ' | ' | '5 years | ' | ' | ' | ' | ' |
Intangible_and_Other_Assets_Es
Intangible and Other Assets Estimated Future Amortization Expense Related to Intangible Assets (Details) (USD $) | Sep. 30, 2013 |
In Thousands, unless otherwise specified | |
Expected Amortization Expense [Line Items] | ' |
2013 remaining 6 months | $21 |
2014 | 69 |
2015 | 50 |
2016 | 28 |
2017 | 28 |
2018 | 23 |
Thereafter | 28 |
Finite-Lived Intangible Assets, Net | $247 |
Intangible_and_Other_Assets_Ot
Intangible and Other Assets Other Assets Narrative (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Refundable deposits | $150 | $154 |
AvailableforSale_Investments_D
Available-for-Sale Investments (Details) (USD $) | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Accumulated other comprehensive income | $327 | ' | $222 |
Liabilities settled with common stock | $84 | $0 | ' |
Fair_Value_Measurements_Fair_V1
Fair Value Measurements Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | $3,225 | $2,963 |
Percent of Total Available-for-sale Investments | 100.00% | 100.00% |
Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,622 | 1,265 |
Percent of Total Available-for-sale Investments | 50.00% | 43.00% |
Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,603 | 1,698 |
Percent of Total Available-for-sale Investments | 50.00% | 57.00% |
Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Percent of Total Available-for-sale Investments | 0.00% | 0.00% |
Cash and Cash Equivalents [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 87 | 32 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 87 | 32 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,242 | 708 |
Common Stock [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,242 | 708 |
Common Stock [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Basic Material [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 22 | 15 |
Common Stock [Member] | Basic Material [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 22 | 15 |
Common Stock [Member] | Basic Material [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Basic Material [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | consumer goods [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 143 | 58 |
Common Stock [Member] | consumer goods [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 143 | 58 |
Common Stock [Member] | consumer goods [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | consumer goods [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Energy [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 120 | 29 |
Common Stock [Member] | Energy [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 120 | 29 |
Common Stock [Member] | Energy [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Energy [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Financial [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 149 | 61 |
Common Stock [Member] | Financial [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 149 | 61 |
Common Stock [Member] | Financial [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Financial [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Healthcare [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 138 | 52 |
Common Stock [Member] | Healthcare [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 138 | 52 |
Common Stock [Member] | Healthcare [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Healthcare [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Industrial Goods [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 158 | 51 |
Common Stock [Member] | Industrial Goods [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 158 | 51 |
Common Stock [Member] | Industrial Goods [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Industrial Goods [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Services [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 34 | 32 |
Common Stock [Member] | Services [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 34 | 32 |
Common Stock [Member] | Services [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Services [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Technology [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 464 | 376 |
Common Stock [Member] | Technology [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 464 | 376 |
Common Stock [Member] | Technology [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Technology [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Transportation [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 8 |
Common Stock [Member] | Transportation [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 8 |
Common Stock [Member] | Transportation [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Transportation [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Utilities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 14 | 26 |
Common Stock [Member] | Utilities [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 14 | 26 |
Common Stock [Member] | Utilities [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Common Stock [Member] | Utilities [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,426 | 1,527 |
Equity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 293 | 525 |
Equity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 1,133 | 1,002 |
Equity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Diversified Emergency Market [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 289 | 187 |
Equity Funds [Member] | Diversified Emergency Market [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Diversified Emergency Market [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 289 | 187 |
Equity Funds [Member] | Diversified Emergency Market [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Foreign Large Blend [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 265 | 244 |
Equity Funds [Member] | Foreign Large Blend [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Foreign Large Blend [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 265 | 244 |
Equity Funds [Member] | Foreign Large Blend [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Foreign Large Growth [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 273 | 250 |
Equity Funds [Member] | Foreign Large Growth [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Foreign Large Growth [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 273 | 250 |
Equity Funds [Member] | Foreign Large Growth [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Global High Yield Income Fund [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 56 | 52 |
Equity Funds [Member] | Global High Yield Income Fund [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Global High Yield Income Fund [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 56 | 52 |
Equity Funds [Member] | Global High Yield Income Fund [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Large Growth [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 250 | 220 |
Equity Funds [Member] | Large Growth [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Large Growth [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 250 | 220 |
Equity Funds [Member] | Large Growth [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Precious Metals [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | ' | 49 |
Equity Funds [Member] | Precious Metals [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | ' | 0 |
Equity Funds [Member] | Precious Metals [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | ' | 49 |
Equity Funds [Member] | Precious Metals [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | ' | 0 |
Equity Funds [Member] | Small Blend [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 293 | 525 |
Equity Funds [Member] | Small Blend [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 293 | 525 |
Equity Funds [Member] | Small Blend [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Equity Funds [Member] | Small Blend [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 470 | 696 |
Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 470 | 696 |
Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | Domestic Corporate Debt Securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 421 | 678 |
Debt Securities [Member] | Domestic Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | Domestic Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 421 | 678 |
Debt Securities [Member] | Domestic Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | Foreign Corporate Debt Securities [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 49 | 18 |
Debt Securities [Member] | Foreign Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 0 | 0 |
Debt Securities [Member] | Foreign Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | 49 | 18 |
Debt Securities [Member] | Foreign Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale Securities, Fair Value disclosure | $0 | $0 |
Notes_Payable_and_Credit_Arran1
Notes Payable and Credit Arrangements Credit Facilitiy Term Disclosure (Details) (USD $) | 0 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | ||||||||||||||||
In Millions, unless otherwise specified | Apr. 30, 2014 | Oct. 29, 2013 | Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Dec. 31, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 18, 2020 | Sep. 18, 2014 | Sep. 30, 2013 | Sep. 18, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Accounts Receivable [Member] | Eligible receivables [Member] | Other eligible receivales billed in foreign currenc [Member] | Eligible Inventory [Member] | Prime Rate [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | |||
Revolving Credit Facility [Member] | Ex-Im Facility [Member] | Streamline eligible under Credit Facility [Member] | Streamline eligible under Credit Facility [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Credit Agreement [Member] | Accounts Receivable [Member] | Prime Rate [Member] | |||||||||
Revolving Credit Facility [Member] | Ex-Im Facility [Member] | Ex-Im Facility [Member] | Ex-Im Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | ||||||||||||||
Line of Credit Facility [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | $1.50 | $1 | $1.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1 | ' | ' |
Line of Credit Facility, Expiration Date | 30-Apr-14 | 29-Oct-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18-Sep-14 | ' | ' | ' | ' | ' |
Debt Instrument, Covenant, Maintaining Liquidity | ' | ' | ' | 1.25 | ' | ' | 3.5 | 2.5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Instrument, Covenant, Maintaining Cash | ' | ' | 2.5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Guidence Line, Capacity Available | ' | ' | ' | 1.5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Eligible Percentage | ' | ' | ' | ' | ' | ' | ' | ' | 80.00% | 90.00% | 75.00% | 50.00% | ' | ' | ' | ' | ' | ' | 75.00% | ' |
Debt Instrument, Basis Spread on Variable Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.50% | ' | ' | ' | ' | ' | ' | 0.50% |
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | ' | 7.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4.50% | ' | ' | ' | ' |
Debt Instrument, Lower Interest Rate | ' | ' | ' | 0.50% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $6 | $6 | ' | ' | ' |
Debt Instrument, Maturity Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18-Sep-20 | ' | ' | ' | ' | ' | ' |
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.75% |
Notes_Payable_and_Credit_Arran2
Notes Payable and Credit Arrangements Line of Credit Period Balances (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 18, 2013 | Sep. 30, 2013 |
Spire Corporation [Member] | Spire Corporation [Member] | Spire Corporation [Member] | Spire Corporation [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | N2 Biomedical LLC [Member] | |||
Revolving Credit Facility [Member] | Revolving Credit Facility [Member] | Ex-Im Facility [Member] | Ex-Im Facility [Member] | Revolving Credit Facility [Member] | |||||
Line of Credit Facility [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Amount Outstanding | ' | ' | $144,000 | $449,000 | $0 | $141,000 | $438,000 | ' | $437,000 |
Long-term Debt | ' | ' | ' | ' | ' | ' | 6,000,000 | 6,000,000 | ' |
Line of Credit Facility, Interest Rate at Period End | ' | ' | 6.50% | ' | 6.50% | ' | ' | ' | 3.75% |
Debt Instrument, Interest Rate at Period End | ' | ' | ' | ' | ' | ' | 4.50% | ' | ' |
Guidence Line, Utilized | ' | 675,000 | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Remaining Borrowing Capacity | $262,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Sharebased_Compensation_StockB
Share-based Compensation Stock-Based Compensation Exepnse (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Employee Service Share-based compensation, Nonvested Awards, Compensation Costs Not yet Recognized, Year One | $8 | ' | $8 | ' |
Employee Service Share-based Compensation, Nonvested awards, Compensation Costs Not yet Recognized, Year Two | 19 | ' | 19 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized | 27 | ' | 27 | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount | ' | ' | 0 | 0 |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition | ' | ' | '0 years 9 months 28 days | ' |
Segment, Continuing Operations [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 11 | 48 | 88 | 169 |
Segment, Continuing Operations [Member] | Cost of Contract Reserach and Services [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 1 | 6 | 11 | 16 |
Segment, Continuing Operations [Member] | Cost of Sales [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 0 | 6 | 7 | 31 |
Segment, Continuing Operations [Member] | Selling, General and Administrative Expenses [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | 10 | 36 | 70 | 122 |
Segment, Discontinued Operations [Member] | ' | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' | ' |
Share-based compensation | $0 | $0 | $0 | ($7) |
Sharebased_Compensation_Stock_
Share-based Compensation Stock Option Plan Additional Information (Details) | 9 Months Ended |
Sep. 30, 2013 | |
optionplans | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Number of Optin Plans | 2 |
Percentage of Fair Market Value | 110.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Award Contractual Term | '10 years |
Sharebased_Compensation_Stock_1
Share-based Compensation Stock Option Activity (Details) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Closing stock price per share | $0.37 | ' |
Weighted-Average Exercise Price [Roll Forward] | ' | ' |
Weighted-Average Exercise Price, Begining balance | $6.21 | ' |
Weighted-Average Exercise Price, Granted | $0.48 | ' |
Weighted-Average Excercise Price, Exercised | $0 | ' |
Weighted-Average Exercise Price, Cancelled/expired | $5.71 | ' |
Weighted-Average Exercise Price, Ending balance | $6.04 | ' |
Weighted-Average Excercise Price, Exercisable at the end of period | $6.08 | ' |
Weighted-Average Excercise Price, Vested and expected to vest at the end of period | $6.07 | ' |
Aggregate Intrinsic Value [Abstract] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value | $0 | $0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | 0 | ' |
Share-based Compensation Arrangement be Share-based Payment Award, Options, Outstanding, Expected to Vest, Weighted Average Remaining Contractual Life | '5 years 3 months 12 days | ' |
Stock Options [Member] | ' | ' |
Number of Shares [Roll Forward] | ' | ' |
Stock Options Number of Shares, Begining balance | 644,446 | ' |
Stock Options Number of Shares, Granted | 26,000 | ' |
Stock Options Number of Shares, Exercised | 0 | ' |
Stock Options Number of Shares, Cancelled/expired | -102,875 | ' |
Stock Options Number of Shares, Ending balance | 567,571 | ' |
Stock Options Number of Shares, Exercisable at the end of the period | 553,821 | ' |
Stock Options Number of Shares, Vested and expected to vest at the end of period | 567,096 | ' |
Common Stock, Capital Shares Reserved for Future Issuance | 438,434 | ' |
Average Remaining Contractual Life (Years) [Abstract] | ' | ' |
Average Remaining Contractual Life, Ending balance (in years) | '5 years 4 months 18 days | ' |
Average Remaining Contractual Life, Exercisable (in years) | '5 years 4 months 1 day | ' |
Average Remaining Contractual Life, Vested and expected to vest at the end of period (in years) | '5 years 4 months 1 day | ' |
Aggregate Intrinsic Value [Abstract] | ' | ' |
Aggregate Intrinsic Value, Outstanding at the ending period, Intrinsic Value | 1,000 | ' |
Aggregate Intrinsic Value, Exercisable at the ending period, Intrinsic Value | 1,000 | ' |
Aggregate Instrinsic Value, Option vested and expected to vest at the end of period, Intrinsic Value | $0 | ' |
Sharebased_Compensation_Stock_2
Share-based Compensation Stock Based Plans Valuation Assumptions (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $0.26 | $0.48 | $0.55 | $1.29 |
Stock Options [Member] | ' | ' | ' | ' |
Expected Dividend Yield | ' | ' | 0.00% | 0.00% |
Risk Free Interest Rate | ' | ' | 1.40% | 0.62% |
Expected Option Life | ' | ' | '5 years 1 month 16 days | '5 years 1 month 16 days |
Expected Volatility Factor | ' | ' | 99.80% | 92.10% |
Accumulated_Other_Comprehensiv3
Accumulated Other Comprehensive Income Changes in Accumulated OCI (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Dec. 31, 2012 |
Accumulated Other Comprehensive Income (Changes in Accumulated Other Comprehensive Income) [Line Items] | ' | ' |
Accumulated Other Comprehensive Income (Loss), Net of Tax | $327 | $222 |
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax | 170 | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax | -65 | ' |
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | $105 | ' |
Accumulated_Other_Comprehensiv4
Accumulated Other Comprehensive Income Reclassifications from Accumulated Other Comprehensive Income (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 |
Accumulated Other Comprehensive Income Reclassifications from Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' | ' |
Selling, general and administrative expenses | $3,381 | $2,934 | $8,466 | $9,338 |
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member] | ' | ' | ' | ' |
Accumulated Other Comprehensive Income Reclassifications from Accumulated Other Comprehensive Income [Line Items] | ' | ' | ' | ' |
Selling, general and administrative expenses | ' | ' | ($65) | ' |
Discontinued_Operations_and_As2
Discontinued Operations and Assets Held for Sale Discontinued Operation Narrative(Details) (USD $) | 3 Months Ended | 9 Months Ended | 0 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 14, 2009 | Sep. 30, 2013 | Sep. 30, 2012 | Mar. 09, 2012 | Mar. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Medical Products Business Unit [Member] | Medical Products Business Unit [Member] | Medical Products Business Unit [Member] | Semiconductor Business Unit [Member] | Semiconductor Business Unit [Member] | Semiconductor Business Unit [Member] | Semiconductor Business Unit [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Disposal Date | ' | ' | ' | ' | 14-Dec-09 | ' | ' | 9-Mar-12 | ' | ' | ' |
Business Divestiture, Sale Price | ' | ' | ' | ' | ' | ' | ' | $8,000,000 | ' | ' | ' |
Proceeds from Divestiture of Businesses | ' | ' | ' | ' | ' | ' | ' | ' | 7,300,000 | ' | ' |
Restricted Cash and Cash Equivalents, Noncurrent | ' | ' | ' | ' | ' | ' | ' | ' | 718,000 | ' | ' |
Business Divestiture, Sale Price Allocation, Liabilities Assume | ' | ' | ' | ' | ' | ' | ' | 500,000 | 1,200,000 | ' | ' |
Business Divestiture, Cost of Divisiture Entity, Transaction Costs | ' | ' | ' | ' | ' | ' | ' | ' | 425,000 | ' | ' |
Loss from discontinued operations before sale of business unit | $0 | ($250,000) | $0 | ($680,000) | ' | $0 | ($250,000) | ' | ' | $0 | ($430,000) |
Discontinued_Operations_and_As3
Discontinued Operations and Assets Held for Sale Discontinued Business Units Assets and Liabilities (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current Assets | ' | ' |
Assets of Disposal Group, Including Discontinued Operation, Current | $0 | $718 |
Current Liabilities | ' | ' |
Total current liabilities of discontinued operations | 21 | 171 |
Medical Products and Semiconductor Business Unit [Member] | ' | ' |
Current Assets | ' | ' |
Disposal Group, Including Discontinued Operation, Other Current Assets | 0 | 718 |
Assets of Disposal Group, Including Discontinued Operation, Current | 0 | 718 |
Total Assets of discontinued operations and assets held for sale | 0 | 718 |
Current Liabilities | ' | ' |
Accrued liabilities | 21 | 171 |
Total current liabilities of discontinued operations | 21 | 171 |
Total liabilities of discontinued operations | $21 | $171 |
Discontinued_Operations_and_As4
Discontinued Operations and Assets Held for Sale Discontinued Business Unit Operations (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' |
Loss from discontinued operations before sale of business unit | $0 | ($250,000) | $0 | ($680,000) |
Gain on sale of business unit, net of transaction expenses | 0 | 0 | 0 | 5,449,000 |
Income tax provision | 0 | 0 | 0 | -2,008,000 |
Income from discontinued operations, net of tax | 0 | -250,000 | 0 | 2,761,000 |
Medical Products and Semiconductor Business Unit [Member] | ' | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' |
Net sales and revenues | 0 | 0 | 0 | 425,000 |
Gross margin | 0 | 0 | 0 | -296,000 |
Loss from discontinued operations before sale of business unit | 0 | -250,000 | 0 | -680,000 |
Gain on sale of business unit, net of transaction expenses | 0 | 0 | 0 | 5,449,000 |
Income tax provision | 0 | 0 | 0 | -2,008,000 |
Income from discontinued operations, net of tax | $0 | ($250,000) | $0 | $2,761,000 |
Variable_Interest_Entity_Detai
Variable Interest Entity (Details) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Dec. 31, 2011 | Sep. 18, 2013 | Sep. 30, 2013 | Sep. 18, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
Corporation [Member] | Corporation [Member] | Biomedical Service [Member] | Biomedical Service [Member] | Convertible Debt [Member] | |||||
sqft | Biomedical Service [Member] | ||||||||
Noncontrolling Interest [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Par or Stated Value Per Share | ' | ' | ' | ' | $6.72 | ' | $6.72 | ' | ' |
Deemed dividend | ' | ' | ' | ' | ' | ' | $9,500,000 | ' | ' |
Proceeds from Divestiture of Businesses | ' | ' | ' | ' | ' | ' | ' | 6,000,000 | ' |
Noncash or Part Noncash Divestiture, Amount of Consideration Received | ' | ' | ' | ' | ' | ' | ' | ' | 2,400,000 |
Disposal Date | ' | ' | ' | ' | ' | ' | 18-Sep-13 | ' | ' |
Cash | 5,897,000 | 3,030,000 | 5,178,000 | 4,758,000 | ' | 276,000 | ' | ' | ' |
Accounts receivable trade, net | 1,363,000 | 2,137,000 | ' | ' | ' | 753,000 | ' | ' | ' |
Inventories, net | 4,656,000 | 5,316,000 | ' | ' | ' | 111,000 | ' | ' | ' |
Prepaid expenses and other current assets | 821,000 | 617,000 | ' | ' | ' | 71,000 | ' | ' | ' |
Total current assets | 13,114,000 | 12,072,000 | ' | ' | ' | 1,211,000 | ' | ' | ' |
Property and equipment, net | 959,000 | 1,197,000 | ' | ' | ' | 211,000 | ' | ' | ' |
Intangible and other assets, net | 397,000 | 393,000 | ' | ' | ' | 88,000 | ' | ' | ' |
Total assets | 17,695,000 | 16,625,000 | ' | ' | ' | 1,510,000 | ' | ' | ' |
Current portion of term loan | 745,000 | 0 | ' | ' | ' | 744,000 | ' | ' | ' |
Revolving line of credit | ' | ' | ' | ' | ' | 438,000 | ' | ' | ' |
Accounts payable | 1,712,000 | 1,424,000 | ' | ' | ' | 91,000 | ' | ' | ' |
Due to Related Parties, Current | ' | ' | ' | ' | ' | 4,000 | ' | ' | ' |
Accrued liabilities | 3,280,000 | 2,221,000 | ' | ' | ' | 197,000 | ' | ' | ' |
Total current liabilities | 7,396,000 | 5,456,000 | ' | ' | ' | 1,474,000 | ' | ' | ' |
Long-term portion of term loan | 5,255,000 | 0 | ' | ' | ' | 5,255,000 | ' | ' | ' |
Related Party Transaction, Due from (to) Related Party | ' | ' | ' | ' | ' | 2,400,000 | ' | ' | ' |
Total liabilities | 16,607,000 | 9,173,000 | ' | ' | ' | 9,129,000 | ' | ' | ' |
Business Divestiture, Sale Price | ' | ' | ' | ' | ' | ' | 10,500,000 | ' | ' |
Business Divestiture, Sale Price Allocation, Liabilities Assume | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' |
Preferred Stock, Shares Outstanding | ' | ' | ' | ' | ' | ' | 310,549 | ' | ' |
Preferred Stock, Value, Issued | ' | ' | ' | ' | ' | ' | $2,100,000 | ' | ' |
Area of Real Estate Property | ' | ' | ' | ' | 27,000 | ' | ' | ' | ' |
Area of real estate property percent | ' | ' | ' | ' | 19.00% | ' | ' | ' | ' |
rent per square foot for first year | ' | ' | ' | ' | 16 | ' | ' | ' | ' |
Rental rate increase on each annual anniversary | ' | ' | ' | ' | 0.5 | ' | ' | ' | ' |